prednisone has been researched along with Dermatomyositis, Adult Type in 364 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effects of the adenine analog, fludarabine, on patients with refractory dermatomyositis and polymyositis, and to assess variables used in following myositis patients during medical intervention." | 9.09 | A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. ( Adams, EM; Bartlett, ML; Fleisher, T; Hicks, JE; McGarvey, C; Plotz, PH; Pucino, F; Sonies, BC; Thornton, B; Villalba, ML; Yarboro, C, 1999) |
| "We observed a severe case of cerebral toxoplasmosis in a 22-year-old woman diagnosed with dermatomyositis in 2016 in Venezuela, and treated with rituximab and azathioprine." | 8.02 | Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis. ( Castaño-Amores, C; Nieto-Gómez, P, 2021) |
| "The prognosis of dermatomyositis (DM)-associated progressive interstitial pneumonia (IP) has recently been improved by steroids/cyclosporine-A (CSA) combination therapy, but treatment outcomes varied." | 7.77 | Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. ( Fujiki, Y; Hanafusa, T; Hata, K; Isoda, K; Kotani, T; Makino, S; Nagai, K; Shiba, H; Takeuchi, T; Yoshida, S, 2011) |
| "We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis." | 7.74 | Leflunomide as adjuvant treatment of dermatomyositis. ( Boswell, JS; Costner, MI, 2008) |
| "Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy." | 7.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
| "To review the experience with high-dose intravenous pulse methylprednisolone (IVMP) therapy in patients with juvenile dermatomyositis (JDM) in our institution." | 7.69 | Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. ( Dooley, J; Lang, B, 1996) |
| "Our purpose was to determine whether low-dose methotrexate administered weekly in combination with other systemic therapies or as a sole systemic agent is effective in the treatment of the cutaneous disease in patients with dermatomyositis." | 7.69 | Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. ( Callen, JP; Kasteler, JS, 1997) |
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 7.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "To investigate the effectiveness of oral chlorambucil treatment in patients with dermatomyositis (DM) that is recalcitrant to treatment with prednisone and/or immunosuppressive agents." | 7.68 | Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. ( Callen, JP; Sinoway, PA, 1993) |
| "To review the clinical course of 16 children with recalcitrant dermatomyositis (DM), who were treated with oral methotrexate (MTX) in addition to prednisone." | 7.68 | Methotrexate treatment of recalcitrant childhood dermatomyositis. ( DeNardo, BA; Miller, LC; Schaller, JG; Sisson, BA; Tucker, LB, 1992) |
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 7.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| "The transcapillary escape rate of albumin was measured in 27 consecutive patients with inflammatory rheumatic diseases before and after 1 and 7 days of prednisone treatment in doses of 45 mg/day." | 7.66 | Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases. ( Hansen, TM; Junker, P; Lorenzen, I; Manthorpe, R; Utne, HE, 1979) |
| "The conditions of three children with dermatomyositis and one child with polymyositis were treated for nine to 31 months with combined prednisone and intravenous methotrexate (1 mg/kg/wk) when prednisone alone was ineffective in controlling the disease or when there were substantial steroid-related toxic effects." | 7.66 | Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. ( Fischer, TJ; Klein, RB; Paulus, HE; Rachelefsky, GS; Stiehm, ER, 1979) |
| "Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series." | 6.82 | Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. ( Allain-Launay, E; Angioloni, S; Apaz, MT; Avcin, T; Bernard-Medina, AG; Bica, B; Bracaglia, C; Brochard, K; Cespedes-Cruz, A; Cimaz, R; Corona, F; Couillault, G; Cuttica, R; Dolezalova, P; Dressler, F; Ferriani, V; Fischbach, M; Flato, B; Gerloni, V; Herlin, T; Joos, R; Magnusson, B; Martini, A; Meini, A; Oliveira, S; Pilkington, C; Pistorio, A; Quartier, P; Ravelli, A; Ruperto, N; Russo, R; Sterba, G; Tardieu, M; Trachana, M; Vargova, V; Wouters, C; Wulffraat, N; Zulian, F, 2016) |
| " The mean starting dosage of MTX in the study group was 15 mg/m(2)/week." | 6.71 | The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. ( Cameron, B; Campbell-Webster, N; Feldman, BM; Laxer, RM; Ota, S; Parker, S; Ramanan, AV; Schneider, R; Silverman, ED; Spiegel, L; Tran, D; Tyrrell, PN, 2005) |
| "Prednisone dose was increased to 0." | 5.43 | [Panniculitis in patient undergoing treatment for dermatomyositis with methotrexate]. ( Feki, NB; Ghorbel, IB; Houman, MH; Khanfir, MS; Said, F, 2016) |
| "Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin." | 5.33 | Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. ( Arbiser, JL; Nadiminti, U, 2005) |
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 5.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| "Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM patients." | 5.30 | The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. ( Cuttica, R; Fischbach, M; Fueri, E; Giancane, G; Lavarello, C; Magnusson, B; Marini, R; Martini, A; Martino, S; Oliveira, SK; Pagnier, A; Pastore, S; Pistorio, A; Ravelli, A; Ruperto, N; Soler, C; Staņēvicha, V; Ten Cate, R; Uziel, Y; Vojinovic, J; Zulian, F, 2019) |
| " In two patients the corticosteroid dosage could be tapered." | 5.27 | Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. ( Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984) |
| "The aims of this pilot study were to assess (1) the safety and tolerability of etanercept in dermatomyositis (DM); (2) the feasibility and safety of a forced prednisone taper; and (3) outcome measures, including those recommended by the International Myositis Assessment Clinical Study (IMACS) group." | 5.15 | A randomized, pilot trial of etanercept in dermatomyositis. ( , 2011) |
| "To study the effects of the adenine analog, fludarabine, on patients with refractory dermatomyositis and polymyositis, and to assess variables used in following myositis patients during medical intervention." | 5.09 | A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. ( Adams, EM; Bartlett, ML; Fleisher, T; Hicks, JE; McGarvey, C; Plotz, PH; Pucino, F; Sonies, BC; Thornton, B; Villalba, ML; Yarboro, C, 1999) |
| "The authors report a 40-year-old Caucasian man with relapsing muscle and skin involvement of dermatomyositis treated with high-dose corticosteroids, taken orally, and methotrexate and human gamma globulin, both administered intravenously." | 4.83 | Acute dermatomyositis with subcutaneous generalized edema. ( Appenzeller, S; Bértolo, MB; Costallat, LT; Werner de Castro, GR, 2006) |
| "A 65-year-old woman with dermatomyositis for which she had been treated for ten years with prednisone (latterly 15 mg daily) suddenly experienced severe pain in the left thoracolumbar region." | 4.79 | [Spontaneous hemothorax in dermatomyositis and long-term glucocorticoid treatment]. ( Bauriedel, G; Bittmann, I; Hertlein, H; Heuck, A; Näbauer, M; Nerlich, A; Schwaiblmair, M; Werdan, K, 1995) |
| "We observed a severe case of cerebral toxoplasmosis in a 22-year-old woman diagnosed with dermatomyositis in 2016 in Venezuela, and treated with rituximab and azathioprine." | 4.02 | Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis. ( Castaño-Amores, C; Nieto-Gómez, P, 2021) |
| " Forty-five patients (27 with polymyositis (PM) and 18 with dermatomyositis (DM)) were included in the study, and all received prednisone therapy." | 3.81 | Increased levels of HSPA5 in the serum of patients with inflammatory myopathies--preliminary findings. ( Tan, JZ; Wang, XF; Xiao, F; Xu, XY, 2015) |
| "We identified all patients treated for PM/DM-ILD and assessed cyclophosphamide (CYC), azathioprine (AZA) and mycophenolate (MMF) when used as first-line steroid sparing therapy for effects on pulmonary function variables, dyspnea and tolerance at six and twelve months." | 3.79 | A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. ( Arrossi, V; Chapman, JT; Culver, DA; Mira-Avendano, IC; Parambil, JG; Xu, M; Yadav, R, 2013) |
| "The prognosis of dermatomyositis (DM)-associated progressive interstitial pneumonia (IP) has recently been improved by steroids/cyclosporine-A (CSA) combination therapy, but treatment outcomes varied." | 3.77 | Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. ( Fujiki, Y; Hanafusa, T; Hata, K; Isoda, K; Kotani, T; Makino, S; Nagai, K; Shiba, H; Takeuchi, T; Yoshida, S, 2011) |
| "We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis." | 3.74 | Leflunomide as adjuvant treatment of dermatomyositis. ( Boswell, JS; Costner, MI, 2008) |
| " Three patients with long-standing polymyositis (PM) or dermatomyositis (DM) poorly responsive to prednisone combined with several immunosuppressants were given intravenous rituximab 1,000 mg on Days 0 and 14." | 3.73 | Rituximab as therapy for refractory polymyositis and dermatomyositis. ( Hausner-Sypek, DL; Noss, EH; Weinblatt, ME, 2006) |
| "To describe the treatment of polymyositis (PM) and dermatomyositis (DM) with prednisone (PRED) and cyclosporin A (CSA) alone or associated with intravenous immunoglobulin (IVIg) and plasmapheresis (PEX)." | 3.71 | Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. ( Danieli, G; Danieli, MG; Logullo, F; Malcangi, G; Palmieri, C; Piani, M; Salvi, A, 2002) |
| "Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy." | 3.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
| "To review the experience with high-dose intravenous pulse methylprednisolone (IVMP) therapy in patients with juvenile dermatomyositis (JDM) in our institution." | 3.69 | Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. ( Dooley, J; Lang, B, 1996) |
| "Our purpose was to determine whether low-dose methotrexate administered weekly in combination with other systemic therapies or as a sole systemic agent is effective in the treatment of the cutaneous disease in patients with dermatomyositis." | 3.69 | Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. ( Callen, JP; Kasteler, JS, 1997) |
| "To evaluate the safety and efficacy of cyclosporin A (CyA) with and without methotrexate (MTX) in refractory juvenile rheumatoid arthritis (JRA) and juvenile dermatomyositis (JDMS)." | 3.69 | Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. ( Bernstein, BH; Franke, E; Rawlings, DJ; Reiff, A; Richardson, L; Shaham, B; Szer, IS, 1997) |
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 3.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "To investigate the effectiveness of oral chlorambucil treatment in patients with dermatomyositis (DM) that is recalcitrant to treatment with prednisone and/or immunosuppressive agents." | 3.68 | Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. ( Callen, JP; Sinoway, PA, 1993) |
| "To review the clinical course of 16 children with recalcitrant dermatomyositis (DM), who were treated with oral methotrexate (MTX) in addition to prednisone." | 3.68 | Methotrexate treatment of recalcitrant childhood dermatomyositis. ( DeNardo, BA; Miller, LC; Schaller, JG; Sisson, BA; Tucker, LB, 1992) |
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 3.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| " We describe 3 consecutive cases complicating dermatomyositis (1 case, anti-Jo-1 antibody negative) and polymyositis (2 cases, anti-Jo-1 antibody positive) in which cyclophosphamide was added to prednisone therapy with favorable outcomes." | 3.67 | Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. ( al-Janadi, M; Karsh, J; Smith, CD, 1989) |
| "Because a seven year old boy with severe dermatomyositis failed to respond to a six week treatment course with prednisone (60 mg/m2) and azathioprine (2 mg/kg/d), five plasma separations were performed." | 3.67 | [Plasma separation in severe juvenile dermatomyositis]. ( Michalk, DV; Scharf, JW, 1985) |
| " Although most children with dermatomyositis have a good prognosis, the best predictor of both good functional recovery and minimal calcinosis is early treatment after the onset of symptoms, using high doses of prednisone for an adequate length of time." | 3.66 | Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. ( Blane, CE; Bowyer, SL; Cassidy, JT; Sullivan, DB, 1983) |
| "Kaposi's sarcoma occurred in a 65-year-old Mexican woman who had been treated for dermatomyositis with prednisone for 2 1/2 years and with azathioprine for four months." | 3.66 | Kaposi's sarcoma in a patient with dermatomyositis receiving immunosuppressive therapy. ( Serushan, M; Weiss, VC, 1982) |
| "Five patients with childhood dermatomyositis, followed for 18 to 96 months, improved when treated with a combination of corticosteroids and methotrexate (one patient) or corticosteroids and cyclophosphamide (four patients) after having become refractory to corticosteroid therapy alone." | 3.66 | Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. ( Bertorini, TE; Niakan, E; Pitner, SE; Whitaker, JN, 1980) |
| "The transcapillary escape rate of albumin was measured in 27 consecutive patients with inflammatory rheumatic diseases before and after 1 and 7 days of prednisone treatment in doses of 45 mg/day." | 3.66 | Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases. ( Hansen, TM; Junker, P; Lorenzen, I; Manthorpe, R; Utne, HE, 1979) |
| "The conditions of three children with dermatomyositis and one child with polymyositis were treated for nine to 31 months with combined prednisone and intravenous methotrexate (1 mg/kg/wk) when prednisone alone was ineffective in controlling the disease or when there were substantial steroid-related toxic effects." | 3.66 | Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. ( Fischer, TJ; Klein, RB; Paulus, HE; Rachelefsky, GS; Stiehm, ER, 1979) |
| " All six patients in the placebo arm crossed over to the 5mg/kg dosing regimen after week 16, and two of those responded to infliximab." | 2.87 | A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. ( Cabalar, IV; Castro, C; Faghihi-Kashani, S; Garg, M; Gourley, M; Harris-Love, MO; Joe, G; Miller, FW; Plotz, PH; Pokrovnichka, A; Schiffenbauer, A; Shrader, J, 2018) |
| "Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series." | 2.82 | Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. ( Allain-Launay, E; Angioloni, S; Apaz, MT; Avcin, T; Bernard-Medina, AG; Bica, B; Bracaglia, C; Brochard, K; Cespedes-Cruz, A; Cimaz, R; Corona, F; Couillault, G; Cuttica, R; Dolezalova, P; Dressler, F; Ferriani, V; Fischbach, M; Flato, B; Gerloni, V; Herlin, T; Joos, R; Magnusson, B; Martini, A; Meini, A; Oliveira, S; Pilkington, C; Pistorio, A; Quartier, P; Ravelli, A; Ruperto, N; Russo, R; Sterba, G; Tardieu, M; Trachana, M; Vargova, V; Wouters, C; Wulffraat, N; Zulian, F, 2016) |
| " The mean starting dosage of MTX in the study group was 15 mg/m(2)/week." | 2.71 | The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. ( Cameron, B; Campbell-Webster, N; Feldman, BM; Laxer, RM; Ota, S; Parker, S; Ramanan, AV; Schneider, R; Silverman, ED; Spiegel, L; Tran, D; Tyrrell, PN, 2005) |
| "Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers." | 2.67 | A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. ( Dalakas, MC; Dambrosia, JM; Dinsmore, ST; Illa, I; McCrosky, S; Otero, C; Soueidan, SA; Stein, DP, 1993) |
| "Dermatomyositis is a rheumatologic illness that very infrequently occurs and during our review of literature only three other cases were reported." | 2.47 | Dermatomyositis and HIV infection: case report and review of the literature. ( Carroll, MB; Holmes, R, 2011) |
| "Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy." | 2.47 | Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought. ( Fett, N; Liu, RH, 2011) |
| "We describe a child with juvenile dermatomyositis who had development of acute fibrinous and organizing pneumonia." | 2.43 | Fatal acute fibrinous and organizing pneumonia in a child with juvenile dermatomyositis. ( Bohnsack, JF; Leslie, KO; Maloney, CG; Prahalad, S, 2005) |
| "Treatment with prednisone and hydroxychloroquine led to complete control of the cutaneous and muscular involvement, which was maintained during prednisone tapering." | 2.42 | Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis. ( Bellosta, M; Bogliolo, L; Caporali, R; Cavagna, L; Montecucco, C, 2004) |
| "Prednisone treatment with hemodialysis improved the situation." | 2.42 | Renal failure in a patient with autosomal dominant polycystic kidney disease and coexisting dermato-polymyositis: first report in the literature. ( Atik, E; Bahceci, F; Karincaoglu, Y; Sari, R; Sarikaya, M; Sevinc, A, 2004) |
| "Dermatomyositis is an idiopathic inflammatory myopathy with characteristic skin manifestations." | 2.41 | Dermatomyositis. ( Koler, RA; Montemarano, A, 2001) |
| "Specific and nonspecific panniculitis sometimes occurs during the course of connective tissue diseases." | 2.41 | Panniculitis: a cutaneous manifestation of dermatomyositis. ( Bosch, J; Cortés, J; Garcia-Patos, V; Jimenez, FJ; Pascual, C; Selva, A; Solans, R; Vilardell, M, 2002) |
| "Among patients, 56% had juvenile idiopathic arthritis (JIA), 29% juvenile systemic lupus erythematosus (JSLE), and 15% juvenile dermatomyositis (JDM)." | 1.72 | COVID-19 quarantine in adolescents with autoimmune rheumatic diseases: mental health issues and life conditions. ( Aikawa, NE; Buscatti, IM; Campos, LMMA; Casella, CB; Elias, AM; Gualano, B; Helito, AC; Ihara, BP; Kozu, KT; Lindoso, LM; Pedroso, CAA; Pereira, RMR; Polanczyk, GV; Queiroz, LB; Setoue, DND; Sieczkowska, SM; Silva, CAA; Simon, JR; Strabelli, CAA; Tanigava, NY; Viana, VSL, 2022) |
| "Calcinosis is an uncommon, but significant clinical feature in adult patients with DM." | 1.62 | Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. ( Jiang, W; Li, S; Tian, X; Wang, G; Yang, H, 2021) |
| "Dermatomyositis is a rare, idiopathic inflammatory myopathy characterized by erythematous skin lesions and inflammation of skeletal muscles." | 1.56 | Autoimmune Conditions: Polymyalgia Rheumatica and Dermatomyositis. ( Ghetu, MV, 2020) |
| "Oral prednisone has been the mainstay of therapy in JDM, and prednisone was reduced faster in patients diagnosed after 1997 when there was also an increase in other medications." | 1.48 | Medications received by patients with juvenile dermatomyositis. ( Bayat, N; Huber, AM; Kishi, T; Mamyrova, G; Miller, FW; Rider, LG; Targoff, IN; Ward, MM; Warren-Hicks, WJ; Wu, L, 2018) |
| "To develop response criteria for juvenile dermatomyositis (DM)." | 1.46 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology Inter ( Aggarwal, R; Bayat, N; Cimaz, R; Constantin, T; Cuttica, RJ; Davidson, JE; de Oliveira, SK; Dressler, F; Erman, B; Feldman, BM; Huber, AM; Lachenbruch, PA; Lindsley, CB; Magalhaes, CS; Magnusson, B; Miller, FW; Pilkington, CA; Pistorio, A; Punaro, M; Ravelli, A; Reed, AM; Rider, LG; Rinaldi, M; Rockette, H; Rouster-Stevens, K; Ruperto, N; Russo, R; van Royen-Kerkhof, A; Vencovsky, J; Villa, L, 2017) |
| "Prednisone dose was increased to 0." | 1.43 | [Panniculitis in patient undergoing treatment for dermatomyositis with methotrexate]. ( Feki, NB; Ghorbel, IB; Houman, MH; Khanfir, MS; Said, F, 2016) |
| "Dermatomyositis-related panniculitis is a rare cutaneous manifestation of dermatomyositis." | 1.42 | Dermatomyositis panniculitis: a case report. ( Carroll, M; Mellick, N; Wagner, G, 2015) |
| " Details regarding the natural course of this disorder, the effects of specific therapies on its progression, and the optimal therapeutic dosage and duration of prednisone are limited." | 1.42 | Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. ( Amato, AA; Arnold, WD; Barohn, RJ; Dimachkie, MM; Gwathmey, K; Heatwole, CR; Hebert, D; Johnson, NE; Kissel, J; McDermott, MP; McVey, AL; Pasnoor, M, 2015) |
| "While dermatomyositis affects thousands of individuals in the United States, laryngeal involvement has only been described in a single case report to date." | 1.39 | Dysphonia and dermatomyositis: an unusual manifestation. ( McNeill, E; Mims, JW; Wood, MW; Wright, SC, 2013) |
| "Juvenile dermatomyositis is a rare systemic vasculopathy that may sometimes present with acute complications." | 1.38 | Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis. ( Bader-Meunier, B; Barnerias, C; Bodemer, C; Chalumeau, M; Costedoat-Chalumeau, N; Gherardi, R; Halphen, I; Lambot-Juhan, K; Monnet, D; Ribeil, JA, 2012) |
| "Calcinosis is a severe manifestation that can be debilitating." | 1.38 | Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. ( Shahani, L, 2012) |
| "Two therapies commonly used to treat psoriasis-phototherapy and tumor necrosis factor-alpha antagonists-must be used with caution in patients with both JDM and psoriasis owing to their potential to exacerbate clinical manifestations of JDM." | 1.37 | Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. ( Jarvis, JN; Kim, NN; Lio, PA; Morgan, GA; Pachman, LM, 2011) |
| "Dermatomyositis has a known association with malignancy." | 1.36 | Early-stage testicular cancer: a rare association with dermatomyositis. ( McLaren, B; Tan, E; Wright, A; Young, D, 2010) |
| "The links between myelofibrosis and autoimmunity are discussed." | 1.35 | [Autoimmune myelofibrosis with dermatomyositis]. ( Delfraissy, JF; Ghosn, J; Goujard, C; Lambotte, O; Lazure, T; Sahali, S, 2009) |
| "Juvenile dermatomyositis is a rare disease." | 1.35 | [Juvenile dermatomyositis: 4 case studies]. ( Afifi, Y; Benzekri, L; Beqqal, K; Hassam, B; Khatibi, I; Khoudri, I; Marcil, T; Meziane, M, 2008) |
| "Treatment with prednisone and methotrexate resulted in complete remission of symptoms." | 1.35 | Dermatomyositis with inclusion body myositis pathology. ( Iverson, D; Layzer, R; Lee, HS; Margeta, M, 2009) |
| "Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin." | 1.33 | Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. ( Arbiser, JL; Nadiminti, U, 2005) |
| "Systemic sclerosis was the most common connective tissue disease associated with IIM, accounting for 42." | 1.33 | Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. ( Goulet, JR; Raymond, Y; Senécal, JL; Targoff, IN; Tremblay, JL; Troyanov, Y, 2005) |
| "A 6-year-old boy with improving juvenile dermatomyositis (JDM) developed severe and debilitating calcinosis, unresponsive to diltiazem and probenecid." | 1.33 | Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. ( Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M, 2005) |
| "Hypersensitivity pneumonitis was suspected." | 1.33 | Recurrent episodes of dermatomyositis-associated pneumonitis masquerading as hypersensitivity pneumonitis. ( Marik, PE; Vahid, B, 2006) |
| "Disseminated superficial actinic porokeratosis is the clinical variant of porokeratosis that most frequently develops in immunosuppressive states." | 1.33 | [Porokeratosis in a patient with dermatomyositis]. ( Cacharrón, JM; de las Heras, C; Durana, C; Ginarte, M; Labandeira, J; Monteagudo-Sánchez, B, 2006) |
| "Lymphocytopenia has been reported in patients with connective tissue diseases, including dermatomyositis (DM)." | 1.32 | Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. ( Bachelez, H; de la Salmonière, P; Dubertret, L; Fouéré, S; Lebbe, C; Morel, P; Rabian, C; Viguier, M, 2003) |
| "A young woman presented with facial myokymia in association with dermatomyositis." | 1.32 | Myokymia, neuromyotonia, dermatomyositis, and voltage-gated K+ channel antibodies. ( Alapati, A; Claussen, GC; Oh, SJ; Vernino, S, 2003) |
| "Interstitial pulmonary fibrosis is a recognized complication of DM, often correlated with antisynthetase enzymes, such as anti-Jo-1." | 1.32 | Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. ( Cohen, JB; Costner, MI; High, WA; Murphy, BA, 2003) |
| "Juvenile dermatomyositis is an uncommon autoimmune disease with classic heliotrope discoloration of the eyelids, erythematous skin rash of joints, and proximal muscle weakness." | 1.31 | Dermatomyositis in two siblings and a brief review of familial dermatomyositis. ( Kissel, JT; Mendell, JR; Tsao, CY, 2002) |
| "Onset of calcinosis was associated with a longer time to diagnosis and treatment (30." | 1.31 | Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. ( Fisler, RE; Fuhlbrigge, RC; Liang, MG; Sundel, RP; Yalcindag, A, 2002) |
| "A case of dermatomyositis presented as bronchiolitis obliterans organizing pneumonia has been rarely reported." | 1.31 | Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. ( Cho, HD; Choi, SJ; Ji, JD; Kang, KH; Kim, HK; Lee, YH; Shim, JJ; Song, GG, 2000) |
| "Dermatomyositis and polymyositis are the two major idiopathic inflammatory myopathies." | 1.31 | [Dermatomyositis and polymyositis: clinical aspects and treatment]. ( Hachulla, E, 2001) |
| "Between 1989 and 1996, 4 cases of Pneumocystis carinii pneumonia (PCP) were observed in patients seronegative for the human immunodeficiency virus who were receiving corticosteroid therapy for dermatomyositis in our institution." | 1.30 | Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. ( Agbalika, F; Bachelez, H; Cadranel, J; Dubertret, L; Mayaud, CM; Mouly, F; Sarfati, C; Schlemmer, B; Schremmer, B, 1997) |
| "Dermatomyositis is associated with significant morbidity and occasional mortality." | 1.30 | Dermatomyositis: a dermatology-based case series. ( Albertson, D; Dawkins, MA; Hinds, A; Jorizzo, JL; Sinal, SH; Walker, FO, 1998) |
| " The lower rate of absorption was associated with a net loss of calcium each day (calculated calcium retention, Vbal, of -35 +/- 14 mg/day compared to +140 +/- 97 mg/day in Group HC, p < 0." | 1.29 | Mineral metabolism in children with dermatomyositis. ( Abrams, SA; Ellis, KJ; Koenning, G; O'Brien, KO; Perez, MD; Stuff, JE, 1994) |
| "Juvenile dermatomyositis is an inflammatory disorder of muscle, skin, and connective tissue." | 1.29 | Proton magnetic resonance imaging and spectroscopic studies of the pathogenesis and treatment of juvenile dermatomyositis. ( Butler, IJ; Jackson, EF; Narayana, PA; Papasozomenos, SC; Slopis, JM, 1993) |
| "Skin biopsy revealed lobular panniculitis, and vacuolar degeneration of epidermal basal cells." | 1.29 | Subcutaneous changes in dermatomyositis. ( Belanyi, P; Fusade, T; Joly, P; Lauret, P; Mihout, MF; Thomine, E, 1993) |
| "We report a case of juvenile dermatomyositis in which clinical onset occurred soon after infection with human parvovirus B19." | 1.29 | Juvenile dermatomyositis in a child infected with human parvovirus B19. ( Dawood, MR; Horne, D; Lewkonia, RM, 1995) |
| " Six years after the start of corticosteroid therapy for her annoying skin lesion, we started to treat her with high-dose intravenous immunoglobulin (IVIG) infusion therapy because of the difficulty of reducing the dosage of oral prednisone, that had secondarily induced adverse effects." | 1.29 | Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin. ( Kikuchi-Numagami, K; Sato, M; Tagami, H, 1996) |
| "A 10-year-old boy had juvenile dermatomyositis and multiple asymmetric lesions of lipoatrophy." | 1.28 | Dermatomyositis associated with multifocal lipoatrophy. ( Commens, C; O'Neill, P; Walker, G, 1990) |
| " Gradual steroid dosage tapering resulted in prompt clinical improvement and marked increases in respiratory muscle strength, maximal inspiratory pressure increasing by 33 percent in one patient and by 70 percent in the other." | 1.28 | Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases. ( Decramer, M; Janssens, S, 1989) |
| " Childhood dermatomyositis is almost uniformly responsive to steroid treatment; there is a good chance of remission with minimal risk of secondary complications with an initial low dosage of prednisone (1 mg/kg/day)." | 1.28 | [Dermatomyositis in children]. ( Dumas, R, 1989) |
| "Polydermatomyositis is a chronic, non-suppurative disease of the striated muscle." | 1.27 | [Polydermatomyositis in the adult and its management]. ( Albert, J; Lamberti, A; Ott, H; Wauthier, D, 1983) |
| "Most autoimmune diseases are responsive to corticosteroids administered in dosages sufficient to shut off the inflammatory process." | 1.27 | Corticosteroids in autoimmune disease. ( Fauci, AS, 1983) |
| "Sixty-six patients with possible juvenile dermatomyositis (JDMS) were observed at the Children's Hospital of Los Angeles from 1960 to 1982." | 1.27 | Course of treated juvenile dermatomyositis. ( Bernstein, BH; Hanson, V; King, KK; Kornreich, HK; Singsen, BH; Spencer, CH, 1984) |
| " In two patients the corticosteroid dosage could be tapered." | 1.27 | Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. ( Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984) |
| "The authors report 28 cases of juvenile dermatomyositis." | 1.27 | [Pediatric dermatomyositis. Apropos of 28 cases]. ( Arthuis, M; Bruguier, A; Clement, MC; Dulac, O; Ponsot, G; Texier, P, 1984) |
| " We retrospectively examined the relationship between serum creatine kinase (CK), muscle strength and the dosage and method of administration of prednisone in 30 patients with PM-DM observed monthly for a minimum of one year." | 1.27 | Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. ( Medsger, TA; Oddis, CV, 1988) |
| " This quantity appears minimal and supplemental dosing of prednisone or modification of administration time would seem to be unnecessary." | 1.27 | [Removal of prednisone and prednisolone during plasma exchange]. ( Assogba, U; Baumelou, A; Durande, JP; Lenoir, G; Pecquinot, MA; Raymond, F; Rottembourg, J, 1988) |
| "Diffuse fasciitis with eosinophilia is a newly recognized connective tissue disease appearing initially to be either scleroderma or dermatomyositis." | 1.26 | Diffuse fasciitis with eosinophilia in childhood. ( Sills, EM, 1982) |
| "Proper diagnosis and treatment of dermatomyositis requires recognition of the frequent disparity between cutaneous and myopathic symptoms." | 1.26 | Dermatomyositis: cutaneous clues to subclinical myositis. ( Waldo, R, 1981) |
| "There is no proved effective treatment of calcinosis which results in functional recovery." | 1.26 | [Prognosis and current treatment of dermatomyositis]. ( Sánchez Yus, E, 1977) |
| "Dermatomyositis is a disease of unknown etiology characterized by muscle weakness and associated with a variety of cutaneous lesions." | 1.26 | Dermatomyositis and Malignancy. ( Vanderploeg, DE, 1977) |
| "Analysis of the response to corticosteroid therapy in a personal series of 8 consecutive cases of dermatomyositis in childhood shows that there are advantages in a moderate dosage, short-term treatment schedule, with gradual tapering of the dosage as soon as there is clinical improvement without waiting for full remission, and in trying to stop steroid therapy within six months rather than following the more prolonged regimen currently still in vogue." | 1.26 | Treatment of dermatomyositis in childhood. ( Dubowitz, V, 1976) |
| " Because of rapid progression of the amyloidosis and further infections, cytotoxic drug therapy was stopped, corticosteroid dosage was decreased, and supplementary immunoglobulin therapy was instituted." | 1.25 | Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy. ( Dawkins, RL; Zilko, PJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 169 (46.43) | 18.7374 |
| 1990's | 51 (14.01) | 18.2507 |
| 2000's | 65 (17.86) | 29.6817 |
| 2010's | 61 (16.76) | 24.3611 |
| 2020's | 18 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Lanis, A | 1 |
| Volochayev, R | 1 |
| Kleiner, DE | 2 |
| Vittal, A | 1 |
| Heller, T | 1 |
| Rider, LG | 6 |
| Shenoi, S | 1 |
| Ihara, BP | 1 |
| Lindoso, LM | 1 |
| Setoue, DND | 1 |
| Tanigava, NY | 1 |
| Helito, AC | 1 |
| Simon, JR | 1 |
| Viana, VSL | 1 |
| Strabelli, CAA | 1 |
| Pedroso, CAA | 1 |
| Sieczkowska, SM | 1 |
| Pereira, RMR | 1 |
| Aikawa, NE | 1 |
| Kozu, KT | 1 |
| Elias, AM | 1 |
| Buscatti, IM | 1 |
| Gualano, B | 1 |
| Queiroz, LB | 1 |
| Casella, CB | 1 |
| Polanczyk, GV | 1 |
| Silva, CAA | 1 |
| Campos, LMMA | 1 |
| Li, S | 2 |
| Sun, Y | 1 |
| Shao, C | 1 |
| Xu, K | 1 |
| Huang, H | 1 |
| Mantero, V | 1 |
| Basilico, P | 1 |
| Pozzetti, U | 1 |
| Tonolo, S | 1 |
| Rossi, G | 1 |
| Spena, G | 1 |
| Rigamonti, A | 1 |
| Salmaggi, A | 1 |
| Chandler, JM | 1 |
| Kim, YJ | 1 |
| Bauer, JL | 1 |
| Wapnir, IL | 1 |
| Bansal, P | 1 |
| Gilbert, EL | 1 |
| Pereira, ROL | 1 |
| Virata, AR | 1 |
| Fenando, A | 1 |
| Firn, K | 1 |
| Louissa, S | 1 |
| Hussain, A | 1 |
| Castaño-Amores, C | 1 |
| Nieto-Gómez, P | 1 |
| Ghetu, MV | 1 |
| Argobi, Y | 1 |
| Fedeles, F | 1 |
| Schoenfeld, SR | 1 |
| Farah, C | 1 |
| Tabesh, OA | 1 |
| Okais, J | 1 |
| Hajjar, A | 1 |
| Haddad, A | 1 |
| Stager, K | 1 |
| Wise, L | 1 |
| Halani, S | 1 |
| Andany, N | 1 |
| Shah, R | 1 |
| Jiang, W | 1 |
| Yang, H | 1 |
| Tian, X | 1 |
| Wang, G | 1 |
| Zhan, X | 1 |
| Yan, W | 1 |
| Wang, Y | 1 |
| Li, Q | 1 |
| Shi, X | 1 |
| Gao, Y | 1 |
| Ye, Q | 1 |
| Nozawa, T | 1 |
| Bell-Peter, A | 1 |
| Doria, AS | 1 |
| Marcuz, JA | 1 |
| Stimec, J | 1 |
| Whitney, K | 1 |
| Feldman, BM | 6 |
| de Andrade, VP | 1 |
| De Souza, FHC | 4 |
| Behrens Pinto, GL | 1 |
| Shinjo, SK | 4 |
| Kartolo, A | 1 |
| Towheed, T | 1 |
| Mates, M | 1 |
| Fronek, L | 1 |
| Bindernagel, R | 1 |
| Segars, K | 1 |
| Miller, R | 1 |
| Ventarola, DJ | 1 |
| Contard, PC | 1 |
| Phelps, RG | 1 |
| Aggarwal, R | 1 |
| Pistorio, A | 4 |
| Bayat, N | 2 |
| Erman, B | 1 |
| Huber, AM | 3 |
| Cimaz, R | 2 |
| Cuttica, RJ | 1 |
| de Oliveira, SK | 1 |
| Lindsley, CB | 3 |
| Pilkington, CA | 1 |
| Punaro, M | 1 |
| Ravelli, A | 4 |
| Reed, AM | 2 |
| Rouster-Stevens, K | 1 |
| van Royen-Kerkhof, A | 2 |
| Dressler, F | 3 |
| Magalhaes, CS | 1 |
| Constantin, T | 1 |
| Davidson, JE | 1 |
| Magnusson, B | 3 |
| Russo, R | 2 |
| Villa, L | 1 |
| Rinaldi, M | 1 |
| Rockette, H | 1 |
| Lachenbruch, PA | 1 |
| Miller, FW | 4 |
| Vencovsky, J | 1 |
| Ruperto, N | 4 |
| Koyama, RVL | 1 |
| Braga, TKK | 1 |
| da Silva Dias, GA | 1 |
| Fujihara, S | 1 |
| Fuzii, HT | 1 |
| Yoshikawa, GT | 1 |
| Terui, H | 1 |
| Yamasaki, K | 1 |
| Yoshida, S | 2 |
| Aiba, S | 1 |
| Ishikawa, M | 1 |
| Yamamoto, T | 1 |
| Besançon, A | 1 |
| Brochard, K | 2 |
| Dupic, L | 1 |
| Gitiaux, C | 1 |
| Delville, M | 1 |
| Krid, S | 1 |
| Quartier, P | 2 |
| Saire, E | 1 |
| Salomon, R | 1 |
| Talbotec, C | 1 |
| Bodemer, C | 2 |
| Bader-Meunier, B | 2 |
| Schiffenbauer, A | 1 |
| Garg, M | 1 |
| Castro, C | 1 |
| Pokrovnichka, A | 1 |
| Joe, G | 1 |
| Shrader, J | 1 |
| Cabalar, IV | 1 |
| Faghihi-Kashani, S | 1 |
| Harris-Love, MO | 1 |
| Plotz, PH | 2 |
| Gourley, M | 1 |
| Parperis, K | 1 |
| Kiyani, A | 1 |
| Koroscil, MT | 1 |
| Rohan, CA | 1 |
| Morris, MJ | 1 |
| Scott, JN | 1 |
| Tidwell, WJ | 1 |
| Callen, JP | 8 |
| Kishi, T | 1 |
| Ward, MM | 1 |
| Wu, L | 1 |
| Mamyrova, G | 2 |
| Targoff, IN | 2 |
| Warren-Hicks, WJ | 1 |
| Gaffney, RG | 1 |
| Werth, VP | 1 |
| Miossi, R | 3 |
| de Moraes, JCB | 1 |
| Bonfá, E | 1 |
| Olivo Pallo, PA | 1 |
| de Araújo, DB | 1 |
| Vilela, VS | 1 |
| Bezerra, MC | 1 |
| Simões, RS | 1 |
| Bernardo, WM | 1 |
| da Cunha, BM | 1 |
| Giancane, G | 1 |
| Lavarello, C | 1 |
| Oliveira, SK | 1 |
| Zulian, F | 2 |
| Cuttica, R | 2 |
| Fischbach, M | 2 |
| Pastore, S | 1 |
| Marini, R | 1 |
| Martino, S | 1 |
| Pagnier, A | 1 |
| Soler, C | 1 |
| Staņēvicha, V | 1 |
| Ten Cate, R | 1 |
| Uziel, Y | 1 |
| Vojinovic, J | 1 |
| Fueri, E | 1 |
| Martini, A | 3 |
| Mira-Avendano, IC | 1 |
| Parambil, JG | 1 |
| Yadav, R | 1 |
| Arrossi, V | 1 |
| Xu, M | 1 |
| Chapman, JT | 1 |
| Culver, DA | 1 |
| Femia, AN | 1 |
| Eastham, AB | 1 |
| Lam, C | 1 |
| Merola, JF | 1 |
| Qureshi, AA | 1 |
| Vleugels, RA | 1 |
| Katz, JD | 1 |
| Jones, OY | 1 |
| Xuan, D | 1 |
| Yu, Y | 1 |
| Shao, L | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Zou, H | 1 |
| Carroll, M | 1 |
| Mellick, N | 1 |
| Wagner, G | 1 |
| Milisenda, JC | 1 |
| Doti, PI | 1 |
| Prieto-González, S | 1 |
| Grau, JM | 2 |
| Malek, A | 1 |
| Raeeskarami, SR | 1 |
| Ziaee, V | 1 |
| Aghighi, Y | 1 |
| Moradinejad, MH | 1 |
| Xiao, F | 1 |
| Tan, JZ | 1 |
| Xu, XY | 1 |
| Wang, XF | 1 |
| Gil, B | 1 |
| Merav, L | 1 |
| Pnina, L | 1 |
| Chagai, G | 1 |
| Johnson, NE | 1 |
| Arnold, WD | 1 |
| Hebert, D | 1 |
| Gwathmey, K | 1 |
| Dimachkie, MM | 1 |
| Barohn, RJ | 1 |
| McVey, AL | 1 |
| Pasnoor, M | 1 |
| Amato, AA | 2 |
| McDermott, MP | 1 |
| Kissel, J | 1 |
| Heatwole, CR | 1 |
| He, JM | 1 |
| Pang, XL | 1 |
| Liang, HJ | 1 |
| Miossec, P | 1 |
| Oliveira, S | 1 |
| Sterba, G | 1 |
| Avcin, T | 1 |
| Corona, F | 1 |
| Gerloni, V | 1 |
| Apaz, MT | 1 |
| Bracaglia, C | 1 |
| Cespedes-Cruz, A | 1 |
| Couillault, G | 1 |
| Joos, R | 1 |
| Tardieu, M | 1 |
| Wulffraat, N | 1 |
| Bica, B | 1 |
| Dolezalova, P | 1 |
| Ferriani, V | 1 |
| Flato, B | 1 |
| Bernard-Medina, AG | 1 |
| Herlin, T | 1 |
| Trachana, M | 1 |
| Meini, A | 1 |
| Allain-Launay, E | 1 |
| Pilkington, C | 1 |
| Vargova, V | 1 |
| Wouters, C | 1 |
| Angioloni, S | 2 |
| Kibbi, N | 1 |
| Bekui, A | 1 |
| Buckley, LM | 1 |
| Koga, T | 1 |
| Mizokami, A | 1 |
| Nakashima, M | 1 |
| Shimizu, T | 1 |
| Nakashima, Y | 1 |
| Nakamura, H | 1 |
| Chiwata, M | 1 |
| Daisuke, N | 1 |
| Kawakami, A | 1 |
| de Inocencio, J | 1 |
| Enríquez-Merayo, E | 1 |
| Casado, R | 1 |
| González-Granado, LI | 1 |
| Bravenboer, B | 1 |
| Debels, L | 1 |
| Nan, X | 1 |
| Adike, A | 1 |
| Rice, L | 1 |
| Bunin, V | 1 |
| Feki, NB | 1 |
| Khanfir, MS | 1 |
| Ghorbel, IB | 1 |
| Said, F | 1 |
| Houman, MH | 1 |
| Dale, A | 1 |
| Milosevic, I | 1 |
| Goldacre, B | 1 |
| Ward, I | 1 |
| Hiles, P | 1 |
| Arroyo, R | 2 |
| Downs, W | 1 |
| Bell, D | 1 |
| Jacks, SK | 1 |
| Zirwas, MJ | 1 |
| Kuye, IO | 1 |
| Smith, GP | 1 |
| Sahali, S | 1 |
| Ghosn, J | 1 |
| Lazure, T | 1 |
| Goujard, C | 1 |
| Delfraissy, JF | 1 |
| Lambotte, O | 1 |
| Seshadri, R | 1 |
| Ilowite, N | 1 |
| Cawkwell, G | 1 |
| Pachman, LM | 4 |
| Marcil, T | 1 |
| Khoudri, I | 1 |
| Meziane, M | 1 |
| Beqqal, K | 1 |
| Khatibi, I | 1 |
| Hassam, B | 1 |
| Afifi, Y | 1 |
| Benzekri, L | 1 |
| Kitaori, T | 1 |
| Ito, H | 1 |
| Yoshitomi, H | 1 |
| Aoyama, T | 1 |
| Fujii, T | 1 |
| Mimori, T | 1 |
| Nakamura, T | 1 |
| Chakour, R | 1 |
| Leimgruber, A | 1 |
| Bart, PA | 2 |
| Spertini, F | 1 |
| Layzer, R | 1 |
| Lee, HS | 1 |
| Iverson, D | 1 |
| Margeta, M | 1 |
| Lieberman, SM | 1 |
| Sherry, DD | 2 |
| Carroll, MB | 1 |
| Holmes, R | 1 |
| Noda, S | 2 |
| Asano, Y | 2 |
| Tamaki, Z | 2 |
| Takekoshi, T | 2 |
| Sugaya, M | 2 |
| Sato, S | 3 |
| Hildebrand, BA | 1 |
| Tan, E | 1 |
| Young, D | 1 |
| McLaren, B | 1 |
| Wright, A | 1 |
| Piovesan, DM | 1 |
| da Silva, VD | 1 |
| Reichel, CL | 1 |
| Baú, P | 1 |
| Hoefel Filho, JR | 1 |
| Staub, HL | 1 |
| Nagai, K | 1 |
| Takeuchi, T | 1 |
| Kotani, T | 1 |
| Hata, K | 1 |
| Isoda, K | 1 |
| Fujiki, Y | 1 |
| Shiba, H | 1 |
| Makino, S | 1 |
| Hanafusa, T | 1 |
| Danieli, MG | 2 |
| Pettinari, L | 1 |
| Moretti, R | 1 |
| Logullo, F | 2 |
| Gabrielli, A | 1 |
| Hirabayashi, M | 1 |
| Yamamoto, M | 1 |
| Hoashi, T | 1 |
| Morimoto, R | 1 |
| Etoh, T | 1 |
| Kaji, K | 1 |
| Fujimoto, M | 1 |
| Kuwana, M | 1 |
| Jiang, X | 2 |
| Yi, Q | 1 |
| Liu, D | 1 |
| Wang, S | 2 |
| Li, L | 1 |
| Fett, N | 1 |
| Liu, RH | 1 |
| Kim, NN | 1 |
| Lio, PA | 1 |
| Morgan, GA | 1 |
| Jarvis, JN | 1 |
| Efthimiou, P | 1 |
| Pokharna, H | 1 |
| Kukar, M | 1 |
| Hennessey, K | 1 |
| Bennàssar, A | 1 |
| Mas, A | 1 |
| Guilabert, A | 1 |
| Julià, M | 1 |
| Mascaró-Galy, JM | 1 |
| Herrero, C | 2 |
| Schiopu, E | 1 |
| Phillips, K | 1 |
| MacDonald, PM | 1 |
| Crofford, LJ | 1 |
| Somers, EC | 1 |
| Monnet, D | 1 |
| Barnerias, C | 1 |
| Halphen, I | 1 |
| Lambot-Juhan, K | 1 |
| Chalumeau, M | 1 |
| Costedoat-Chalumeau, N | 1 |
| Ribeil, JA | 1 |
| Gherardi, R | 1 |
| Shahani, L | 1 |
| McClanahan, CM | 1 |
| Smith, HL | 1 |
| Garner, SA | 1 |
| Wood, MW | 1 |
| McNeill, E | 1 |
| Mims, JW | 1 |
| Wright, SC | 1 |
| Tsao, CY | 1 |
| Mendell, JR | 1 |
| Kissel, JT | 1 |
| Fisler, RE | 1 |
| Liang, MG | 1 |
| Fuhlbrigge, RC | 1 |
| Yalcindag, A | 1 |
| Sundel, RP | 1 |
| Mercado, U | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Zhang, M | 1 |
| Cheng, N | 1 |
| Viguier, M | 1 |
| Fouéré, S | 1 |
| de la Salmonière, P | 1 |
| Rabian, C | 1 |
| Lebbe, C | 1 |
| Dubertret, L | 2 |
| Morel, P | 1 |
| Bachelez, H | 2 |
| Oh, SJ | 1 |
| Alapati, A | 1 |
| Claussen, GC | 1 |
| Vernino, S | 1 |
| Hall, VC | 1 |
| Keeling, JH | 1 |
| Davis, MD | 1 |
| Hoffman, AH | 1 |
| Bernreuter, W | 1 |
| Alarcón, GS | 1 |
| Botsios, C | 1 |
| Ostuni, P | 1 |
| Boscolo-Rizzo, P | 1 |
| Da Mosto, MC | 1 |
| Punzi, L | 1 |
| Marchiori, C | 1 |
| High, WA | 1 |
| Cohen, JB | 2 |
| Murphy, BA | 1 |
| Costner, MI | 2 |
| BASSET, A | 2 |
| MONFORT, J | 2 |
| DYK, T | 1 |
| MICKS, RH | 1 |
| MULLANEY, J | 1 |
| FLAMM, S | 1 |
| MACKIEWICZ, S | 1 |
| ZIMMERMANN, I | 1 |
| TELLEZMAGANA, J | 1 |
| HERMOSILLADIAZ, F | 1 |
| SANCHEZ, J | 1 |
| SOTO, O | 1 |
| ALIAGA, C | 1 |
| SALDIAS, E | 1 |
| RUGGIERO, HA | 1 |
| PEARSON, CM | 6 |
| BERGOEND, H | 1 |
| FOWLER, WM | 1 |
| HEPPER, NG | 1 |
| FERGUSON, RH | 1 |
| HOWARD, FM | 1 |
| HERD, JK | 1 |
| VAUGHAN, JH | 1 |
| BELLOT, SM | 1 |
| SACREZ, R | 2 |
| PAIRA, M | 1 |
| VOGEL, R | 1 |
| Gainon, J | 1 |
| Waeber, G | 1 |
| Mroué, KH | 1 |
| Sharara, NH | 1 |
| Rbeiz, JG | 1 |
| Arayssi, TK | 1 |
| Caporali, R | 1 |
| Cavagna, L | 1 |
| Bellosta, M | 1 |
| Bogliolo, L | 1 |
| Montecucco, C | 1 |
| López Escobar García-Prendes, M | 1 |
| Raya Aguado, C | 1 |
| Vázquez López, F | 1 |
| Pérez Oliva, N | 1 |
| Weinel, S | 1 |
| Knox-Macaulay, HH | 1 |
| Adil, SN | 1 |
| Ahmed, EM | 1 |
| Bahceci, F | 1 |
| Sari, R | 1 |
| Sarikaya, M | 1 |
| Atik, E | 1 |
| Karincaoglu, Y | 1 |
| Sevinc, A | 1 |
| Hengstman, GJ | 1 |
| van den Hoogen, FH | 1 |
| van Engelen, BG | 2 |
| Waldman, MA | 1 |
| Prahalad, S | 1 |
| Bohnsack, JF | 1 |
| Maloney, CG | 1 |
| Leslie, KO | 1 |
| Nadiminti, U | 1 |
| Arbiser, JL | 1 |
| Rudge, S | 1 |
| Hailwood, S | 1 |
| Horne, A | 1 |
| Lucas, J | 1 |
| Wu, F | 1 |
| Cundy, T | 1 |
| Kilani, B | 1 |
| Amari, L | 1 |
| Houmane, H | 1 |
| Ben Châabane, T | 1 |
| Troyanov, Y | 1 |
| Tremblay, JL | 1 |
| Goulet, JR | 1 |
| Raymond, Y | 1 |
| Senécal, JL | 1 |
| Ambler, GR | 1 |
| Chaitow, J | 1 |
| Rogers, M | 1 |
| McDonald, DW | 1 |
| Ouvrier, RA | 1 |
| Hoogendijk, JE | 1 |
| Bijlsma, JW | 1 |
| Lindeman, E | 1 |
| de Rie, MA | 1 |
| de Visser, M | 1 |
| Jennekens, FG | 1 |
| Goodall, J | 1 |
| Usatine, RP | 1 |
| Buriot, D | 1 |
| Scheinmann, P | 1 |
| Meyer, B | 1 |
| Vialatte, J | 1 |
| Ramanan, AV | 1 |
| Campbell-Webster, N | 1 |
| Ota, S | 1 |
| Parker, S | 1 |
| Tran, D | 1 |
| Tyrrell, PN | 1 |
| Cameron, B | 1 |
| Spiegel, L | 1 |
| Schneider, R | 1 |
| Laxer, RM | 1 |
| Silverman, ED | 1 |
| Werner de Castro, GR | 1 |
| Appenzeller, S | 1 |
| Bértolo, MB | 1 |
| Costallat, LT | 1 |
| Simeoni, S | 1 |
| Puccetti, A | 1 |
| Moruzzi, S | 1 |
| Tinazzi, E | 1 |
| Peterlana, D | 1 |
| Lunardi, C | 1 |
| Bergler-Czop, B | 1 |
| Brzezińska-Wcisło, L | 1 |
| Lis, A | 1 |
| Krauze, E | 1 |
| Marszał, E | 1 |
| Jamroz, E | 1 |
| Klimek, B | 1 |
| Kajor, M | 1 |
| Noss, EH | 1 |
| Hausner-Sypek, DL | 1 |
| Weinblatt, ME | 1 |
| Rowin, J | 1 |
| Deisher, N | 1 |
| Cursio, J | 1 |
| Meriggioli, MN | 1 |
| Dold, S | 1 |
| Justiniano, ME | 1 |
| Marquez, J | 1 |
| Espinoza, LR | 1 |
| Muslimani, A | 1 |
| Ahluwalia, MS | 1 |
| Palaparty, P | 1 |
| Daw, HA | 1 |
| Huppertz, HI | 1 |
| Vahid, B | 1 |
| Marik, PE | 1 |
| Monteagudo-Sánchez, B | 1 |
| Ginarte, M | 1 |
| Durana, C | 1 |
| Labandeira, J | 1 |
| de las Heras, C | 1 |
| Cacharrón, JM | 1 |
| James-Newton, L | 1 |
| Shaham, B | 2 |
| Arnson, Y | 1 |
| Dovrish, Z | 1 |
| Hadari, R | 1 |
| Amital, H | 1 |
| Mañas, MD | 1 |
| Marchán, E | 1 |
| Calderón, P | 1 |
| Lara, P | 1 |
| Lee, LA | 1 |
| Hobbs, KF | 1 |
| Magro, CM | 1 |
| Schaefer, JT | 1 |
| Waldman, J | 1 |
| Knight, D | 1 |
| Seilstad, K | 1 |
| Hearne, D | 1 |
| Boswell, JS | 1 |
| Nguyen, BD | 1 |
| Roarke, MC | 1 |
| McCullough, AE | 1 |
| Cohran, VC | 1 |
| Griffiths, M | 1 |
| Heubi, JE | 1 |
| Askari, AD | 2 |
| Huettner, TL | 1 |
| Albert, J | 1 |
| Lamberti, A | 1 |
| Ott, H | 1 |
| Wauthier, D | 1 |
| Kaplan, D | 1 |
| Dickey, BF | 1 |
| Myers, AR | 1 |
| Fauci, AS | 1 |
| Spencer, CH | 1 |
| Hanson, V | 1 |
| Singsen, BH | 1 |
| Bernstein, BH | 2 |
| Kornreich, HK | 1 |
| King, KK | 1 |
| Shi, GY | 1 |
| Nussbaum, AI | 1 |
| Silver, RM | 1 |
| Maricq, HR | 1 |
| Bowyer, SL | 2 |
| Blane, CE | 1 |
| Sullivan, DB | 4 |
| Cassidy, JT | 3 |
| Woo, TY | 1 |
| Voorhees, JJ | 1 |
| Bickers, DR | 1 |
| Hanno, R | 1 |
| Hawkins, C | 1 |
| Bruguier, A | 2 |
| Texier, P | 2 |
| Clement, MC | 1 |
| Dulac, O | 1 |
| Ponsot, G | 2 |
| Arthuis, M | 2 |
| Sluzewski, W | 1 |
| Patrone, NA | 1 |
| Ganser, G | 1 |
| Spieker, C | 1 |
| Raidt, H | 1 |
| Zidek, W | 1 |
| Lison, AE | 1 |
| Vetter, H | 1 |
| O'Neill, M | 1 |
| Basheer, SM | 1 |
| Hanauer, LB | 1 |
| Cooke, N | 1 |
| Harrist, TJ | 1 |
| Mihm, MC | 1 |
| Weiss, VC | 1 |
| Serushan, M | 1 |
| Kobíková, M | 1 |
| Fucíková, T | 1 |
| Morán-Vázquez, JO | 1 |
| Santana-Lomelí, O | 1 |
| Viruete-Alcaraz, M | 1 |
| García-Pérez, J | 1 |
| Jasso-Urzúa, H | 1 |
| Sills, EM | 1 |
| Niakan, E | 1 |
| Pitner, SE | 1 |
| Whitaker, JN | 1 |
| Bertorini, TE | 1 |
| Waldo, R | 1 |
| Renault, F | 1 |
| Raimbault, J | 1 |
| Roy, C | 1 |
| Harpey, JP | 1 |
| Laget, P | 1 |
| Roach, DG | 1 |
| Salter, WM | 1 |
| Resnick, JS | 1 |
| Mammel, M | 1 |
| Mundale, MO | 1 |
| Kottke, FJ | 1 |
| Dau, PC | 1 |
| Bennington, JL | 1 |
| Smadja, D | 1 |
| Bellance, R | 1 |
| Cabre, P | 1 |
| Arfi, S | 1 |
| Vernant, JC | 1 |
| Clarke, AE | 1 |
| Bloch, DA | 1 |
| Medsger, TA | 2 |
| Oddis, CV | 2 |
| Trüeb, RM | 1 |
| Becker-Wegerich, P | 1 |
| Hafner, J | 1 |
| Wüthrich, B | 1 |
| Burg, G | 1 |
| Faure Fontenla, MA | 1 |
| Endo, T | 1 |
| Kawaguchi, N | 1 |
| Yashima, M | 1 |
| Tei, H | 1 |
| Hayakawa, H | 1 |
| Perez, MD | 1 |
| Abrams, SA | 1 |
| Koenning, G | 1 |
| Stuff, JE | 1 |
| O'Brien, KO | 1 |
| Ellis, KJ | 1 |
| de Toro Santos, FJ | 1 |
| Verea-Hernando, H | 1 |
| Montero, C | 1 |
| Blanco-Aparicio, M | 1 |
| Torres Lanzas, J | 1 |
| Pombo Felipe, F | 1 |
| Yu, B | 1 |
| King, LE | 1 |
| Park, JH | 1 |
| Adams, LB | 1 |
| Olsen, NJ | 1 |
| Bauriedel, G | 1 |
| Schwaiblmair, M | 1 |
| Näbauer, M | 1 |
| Heuck, A | 1 |
| Hertlein, H | 1 |
| Bittmann, I | 1 |
| Nerlich, A | 1 |
| Werdan, K | 1 |
| Kahn, SJ | 1 |
| el Alaoui-Faris, M | 1 |
| Benabdeljalil, M | 1 |
| Slassi, I | 1 |
| Boutchiche, M | 1 |
| Birouk, N | 1 |
| Belaidi, H | 1 |
| Saidi, A | 1 |
| Chkili, T | 1 |
| Davidson, GS | 1 |
| Voorneveld, CR | 1 |
| Krishnan, N | 1 |
| Fafalak, RG | 1 |
| Peterson, MG | 1 |
| Kagen, LJ | 1 |
| Hachulla, E | 2 |
| Lecat, N | 1 |
| Messin, R | 1 |
| Casademont, J | 1 |
| Fernández-Solà, J | 1 |
| Urbano-Márquez, A | 1 |
| Touton, B | 1 |
| Lecerf, V | 1 |
| Crickx, B | 1 |
| Picard, C | 1 |
| Michaud, V | 1 |
| L'Anthoën-Arditi, MH | 1 |
| Belaïch, S | 1 |
| Dalakas, MC | 1 |
| Illa, I | 1 |
| Dambrosia, JM | 1 |
| Soueidan, SA | 1 |
| Stein, DP | 1 |
| Otero, C | 1 |
| Dinsmore, ST | 1 |
| McCrosky, S | 1 |
| Wokke, JH | 1 |
| Slopis, JM | 1 |
| Jackson, EF | 1 |
| Narayana, PA | 1 |
| Papasozomenos, SC | 1 |
| Butler, IJ | 1 |
| Mehregan, DR | 1 |
| Su, WP | 1 |
| Sinoway, PA | 1 |
| Fusade, T | 1 |
| Belanyi, P | 1 |
| Joly, P | 1 |
| Thomine, E | 1 |
| Mihout, MF | 1 |
| Lauret, P | 1 |
| Hu, WJ | 1 |
| Chen, DL | 1 |
| Min, HQ | 1 |
| Lewkonia, RM | 1 |
| Horne, D | 1 |
| Dawood, MR | 1 |
| Kikuchi-Numagami, K | 1 |
| Sato, M | 1 |
| Tagami, H | 1 |
| Lang, B | 2 |
| Dooley, J | 1 |
| Solomon, JE | 1 |
| D'Alton, ME | 1 |
| Watanabe, T | 1 |
| Tsuchida, T | 1 |
| Furue, M | 1 |
| Yoshinoya, S | 1 |
| Kasteler, JS | 1 |
| Kalenian, M | 1 |
| Zweiman, B | 1 |
| Rosenbach, K | 1 |
| Brown, M | 1 |
| Matfin, G | 1 |
| Adelman, HM | 1 |
| Federman, DG | 1 |
| Kirsner, RS | 1 |
| Braverman, IM | 1 |
| Schremmer, B | 1 |
| Cadranel, J | 2 |
| Mouly, F | 1 |
| Sarfati, C | 1 |
| Agbalika, F | 1 |
| Schlemmer, B | 1 |
| Mayaud, CM | 1 |
| Buderus, S | 1 |
| Wagner, N | 1 |
| Lentze, MJ | 1 |
| Tierney, D | 1 |
| Jirjis, JN | 1 |
| Reiff, A | 1 |
| Rawlings, DJ | 1 |
| Franke, E | 1 |
| Richardson, L | 1 |
| Szer, IS | 1 |
| Larenas-Linnemann, DE | 1 |
| Berrón-Perez, R | 1 |
| Ortega-Martell, JA | 1 |
| Onuma-Takane, E | 1 |
| Huicochea-Grobet, Z | 1 |
| Dawkins, MA | 1 |
| Jorizzo, JL | 1 |
| Walker, FO | 1 |
| Albertson, D | 1 |
| Sinal, SH | 1 |
| Hinds, A | 1 |
| Xue, L | 1 |
| Chen, X | 1 |
| Chen, S | 1 |
| Adams, EM | 1 |
| Pucino, F | 1 |
| Yarboro, C | 1 |
| Hicks, JE | 1 |
| Thornton, B | 1 |
| McGarvey, C | 1 |
| Sonies, BC | 1 |
| Bartlett, ML | 1 |
| Villalba, ML | 1 |
| Fleisher, T | 1 |
| Knoell, KA | 1 |
| Hook, M | 1 |
| Grice, DP | 1 |
| Hendrix, JD | 1 |
| Lee, YH | 1 |
| Choi, SJ | 1 |
| Ji, JD | 1 |
| Shim, JJ | 1 |
| Kang, KH | 1 |
| Cho, HD | 1 |
| Kim, HK | 1 |
| Song, GG | 1 |
| LeBlanc, CM | 1 |
| Birdi, N | 1 |
| Bolaria, RK | 1 |
| Malleson, P | 1 |
| MacNeil, I | 1 |
| Momy, JA | 1 |
| Avery, G | 1 |
| Alexanderson, H | 1 |
| Stenström, CH | 1 |
| Jenner, G | 1 |
| Lundberg, I | 1 |
| Qushmaq, KA | 1 |
| Chalmers, A | 1 |
| Esdaile, JM | 1 |
| Song, X | 1 |
| Peng, J | 1 |
| Qiu, Q | 1 |
| Al-Mayouf, SM | 1 |
| Al-Eid, W | 1 |
| Bahabri, S | 1 |
| Al-Mofada, S | 1 |
| Koler, RA | 1 |
| Montemarano, A | 1 |
| Malcangi, G | 1 |
| Palmieri, C | 1 |
| Salvi, A | 1 |
| Piani, M | 1 |
| Danieli, G | 1 |
| Climent-Albaladejo, A | 1 |
| Saiz-Cuenca, E | 1 |
| Rosique-Roman, J | 1 |
| Caballero-Rodriguez, J | 1 |
| Galvez-Munoz, J | 1 |
| Solans, R | 1 |
| Cortés, J | 1 |
| Selva, A | 1 |
| Garcia-Patos, V | 1 |
| Jimenez, FJ | 1 |
| Pascual, C | 1 |
| Bosch, J | 1 |
| Vilardell, M | 1 |
| Manthorpe, R | 1 |
| Hansen, TM | 1 |
| Junker, P | 1 |
| Lorenzen, I | 1 |
| Utne, HE | 1 |
| Zilko, PJ | 1 |
| Dawkins, RL | 2 |
| Lipsmeyer, EA | 1 |
| Lewis, RB | 1 |
| Vasilescu, C | 1 |
| Bucur, G | 1 |
| Petrovici, A | 1 |
| Florescu, A | 1 |
| Petty, RE | 2 |
| Miller, JJ | 1 |
| Koehler, JP | 1 |
| Jacobs, JC | 2 |
| Fishbein, E | 1 |
| Ramos-Niembro, F | 1 |
| Alarcon-Segovia, D | 1 |
| Lell, ME | 1 |
| Swerdlow, ML | 1 |
| Bohan, A | 2 |
| Mazzei, D | 1 |
| Polli, EE | 1 |
| Quarto di Palo, F | 1 |
| Metheny, JA | 1 |
| Jerusalem, F | 1 |
| Sánchez Yus, E | 1 |
| Fischer, TJ | 1 |
| Rachelefsky, GS | 1 |
| Klein, RB | 1 |
| Paulus, HE | 1 |
| Stiehm, ER | 1 |
| Patri, B | 1 |
| Roswag, D | 1 |
| Vilde, F | 1 |
| Menez, F | 1 |
| Dubrisay, J | 1 |
| Giannini, M | 1 |
| Kagan, LJ | 1 |
| Janul, LC | 1 |
| Ansell, BM | 1 |
| Wirth, W | 1 |
| Diekmann, L | 1 |
| Klokenbusch, S | 1 |
| Fierro, B | 1 |
| Raimondo, DM | 1 |
| Smorto, MP | 1 |
| Puff, KH | 1 |
| Vanderploeg, DE | 1 |
| Ludatscher, R | 1 |
| Gellei, B | 1 |
| Guershoni, G | 1 |
| Benderley, A | 1 |
| de Crousaz, H | 1 |
| Juillard, E | 1 |
| Bach, J | 1 |
| van Ballegooie, E | 1 |
| Casparie, AF | 1 |
| Bradley, WG | 1 |
| Walton, JN | 3 |
| Dubowitz, V | 1 |
| Leddy, JP | 1 |
| Griggs, RC | 1 |
| Klemperer, MR | 1 |
| Frank, MM | 1 |
| Park, S | 1 |
| Nyhan, WL | 2 |
| Healey, LA | 1 |
| Miller, LC | 2 |
| Sisson, BA | 1 |
| Tucker, LB | 1 |
| DeNardo, BA | 1 |
| Schaller, JG | 2 |
| Pereira, RM | 1 |
| Lerner, S | 1 |
| Maeda, WT | 1 |
| Goldenstein-Schainberg, C | 1 |
| Cossermelli, W | 1 |
| Euwer, RL | 1 |
| Sontheimer, RD | 1 |
| Flammang d'Ortho, MP | 1 |
| Milleron, B | 1 |
| Zalcman, G | 1 |
| Arvin-Berod, C | 1 |
| Terrioux, P | 1 |
| Akoun, G | 1 |
| Hayashi, Y | 1 |
| Kikuchi-Tada, A | 1 |
| Jitsukawa, K | 1 |
| Anzai, T | 1 |
| Fain, O | 1 |
| Rainfray, M | 1 |
| Callard, P | 1 |
| Guillevin, L | 2 |
| Meyrier, A | 1 |
| Commens, C | 1 |
| O'Neill, P | 1 |
| Walker, G | 1 |
| Olson, NY | 1 |
| al-Janadi, M | 1 |
| Smith, CD | 1 |
| Karsh, J | 1 |
| Rosenzweig, BA | 1 |
| Rotmensch, S | 1 |
| Binette, SP | 1 |
| Phillippe, M | 1 |
| Mintz, G | 1 |
| Boudes, P | 1 |
| Dalakas, M | 1 |
| Janssens, S | 1 |
| Decramer, M | 1 |
| Dumas, R | 1 |
| Haguenau, M | 1 |
| Piette, JC | 1 |
| Robert, G | 1 |
| Cohen, BH | 1 |
| Sedwick, LA | 1 |
| Burde, RM | 1 |
| Lane, RJ | 1 |
| Fulthorpe, JJ | 1 |
| Hudgson, P | 1 |
| Mastaglia, FL | 1 |
| Ojeda, VJ | 1 |
| Rodríguez Núñez, A | 1 |
| Fernández Bustillo, JM | 1 |
| Rodríguez Pérez, E | 1 |
| Novo Rodríguez, I | 1 |
| Pérez Becerra, E | 1 |
| Peña Guitián, J | 1 |
| Castro Gago, M | 1 |
| Leonard-Segal, A | 1 |
| Johnson, JJ | 1 |
| Nashel, DJ | 1 |
| Assogba, U | 1 |
| Baumelou, A | 1 |
| Pecquinot, MA | 1 |
| Raymond, F | 1 |
| Durande, JP | 1 |
| Lenoir, G | 1 |
| Rottembourg, J | 1 |
| Thomas, JW | 1 |
| Vertkin, A | 1 |
| Nell, LJ | 1 |
| Gruhn, WB | 1 |
| Diaz-Buxo, JA | 1 |
| García Consuegra, J | 1 |
| Antelo, MC | 1 |
| Torreblanca, J | 1 |
| Kingston, WJ | 1 |
| Moxley, RT | 1 |
| Kamphuis, DJ | 1 |
| Carpentier, PJ | 1 |
| van der Ploeg, RJ | 1 |
| le Coultre, R | 1 |
| Burgos-Vargas, R | 1 |
| Vázquez-Mellado, J | 1 |
| Gómez-Gordillo y Ruelas, M | 1 |
| Katona, G | 1 |
| Michael, AF | 1 |
| Kim, Y | 1 |
| McKendry, RJ | 1 |
| Clark, RA | 1 |
| Ragsdale, CG | 1 |
| Hollister, JR | 1 |
| Lovell, HB | 1 |
| Holden, DJ | 1 |
| Brownell, AK | 1 |
| Fritzler, MJ | 1 |
| Baron, M | 1 |
| Small, P | 1 |
| Wallach, D | 1 |
| Carado, Y | 1 |
| Foldès, C | 1 |
| Cottenot, F | 1 |
| Scharf, JW | 1 |
| Michalk, DV | 1 |
| Hatron, PY | 1 |
| Wallaert, B | 1 |
| Fourrier, JL | 1 |
| Fournier, E | 1 |
| Gosselin, B | 1 |
| Devulder, B | 1 |
| Wallace, DJ | 1 |
| Metzger, AL | 2 |
| White, KK | 1 |
| Sokoloff, MC | 1 |
| Goldberg, LS | 2 |
| Dinsdale, SM | 1 |
| Cole, TM | 1 |
| Zaki, FG | 1 |
| Awad, EA | 1 |
| Krosch, H | 1 |
| Schäbitz, J | 1 |
| Rikirsch, P | 1 |
| Aguilar, AR | 1 |
| Gomez, F | 1 |
| Balsa, FT | 1 |
| Framil, JP | 1 |
| Oubina, PN | 1 |
| Schrago, R | 1 |
| Miescher, PA | 1 |
| Malaviya, AN | 1 |
| Many, A | 1 |
| Schwartz, RS | 1 |
| Robitaille, P | 1 |
| Garbsch, H | 1 |
| Radl, H | 1 |
| Brühl, W | 1 |
| Spiessens, H | 1 |
| Wellens, W | 1 |
| Schmidt-Peter, P | 1 |
| Pfeil, B | 1 |
| Richier, JL | 1 |
| Guérin, D | 1 |
| Leblay, R | 1 |
| Pony, JC | 1 |
| Hill, RH | 1 |
| Wood, WS | 1 |
| Eisen, AA | 1 |
| Norris, JW | 1 |
| Klemm, D | 1 |
| Emmrich, R | 1 |
| Sieńkowska, I | 1 |
| Gotoff, SP | 1 |
| Smith, RD | 1 |
| Sugar, O | 1 |
| Etienne, JP | 1 |
| Labayle, D | 1 |
| Chaput, JC | 1 |
| Buffet, C | 1 |
| Webb, DR | 1 |
| Currie, GD | 1 |
| Tsai, A | 1 |
| Lindheimer, MD | 1 |
| Lamberg, SI | 1 |
| Banzhaf, M | 1 |
| Göpel, W | 1 |
| Susac, JO | 1 |
| Garcia-Mullin, R | 1 |
| Glaser, JS | 1 |
| Vail, JT | 1 |
| Porubsky, ES | 1 |
| Murray, JP | 1 |
| Pratt, LL | 1 |
| Gross, S | 1 |
| Maskaleris, ML | 1 |
| Arnett, FC | 1 |
| Whelton, JC | 1 |
| Zizic, TM | 1 |
| Stevens, MB | 1 |
| Frazier, AR | 1 |
| Miller, RD | 1 |
| Rose, AL | 1 |
| Bluestone, R | 1 |
| Burt, A | 1 |
| Olsen, GN | 1 |
| Swenson, EW | 1 |
| Lever, WF | 1 |
| Nebe, H | 1 |
| Kessler, E | 1 |
| Weinberger, I | 1 |
| Rosenfeld, JB | 1 |
| Rothstein, TL | 1 |
| Carlson, CB | 1 |
| Sumi, SM | 1 |
| Notermans, SL | 1 |
| Marks, AD | 1 |
| Lieberman, F | 1 |
| Cruchaud, A | 1 |
| Bagdade, JD | 1 |
| Porte, D | 1 |
| Bierman, EL | 1 |
| Medenica, N | 1 |
| Coughlin, DF | 1 |
| Fawcett, NP | 1 |
| Hasert, K | 1 |
| Stroud, JD | 1 |
| Van Dersarl, JV | 1 |
| Thompson, JE | 1 |
| Rollier, MR | 1 |
| Rollier, M | 1 |
| Pichler, E | 1 |
| Weaver, AL | 1 |
| Brundage, BH | 1 |
| Nelson, RA | 1 |
| Bischoff, MB | 1 |
| Marill, FG | 1 |
| Grould, P | 1 |
| Baer, RL | 1 |
| Chernosky, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis[NCT00033891] | Phase 2 | 14 participants (Actual) | Interventional | 2002-04-10 | Completed | ||
| Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis[NCT05524311] | Phase 2 | 16 participants (Anticipated) | Interventional | 2022-11-10 | Recruiting | ||
| Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes[NCT03936829] | 10 participants (Anticipated) | Interventional | 2019-04-28 | Recruiting | |||
| Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate[NCT00323960] | Phase 3 | 139 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group[NCT02375867] | Phase 4 | 33 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Evaluation of Circulating PlexinD1 as a Potential Biomarker of Polymyositis and Dermatomyositis.[NCT05637931] | 66 participants (Anticipated) | Observational | 2022-12-25 | Not yet recruiting | |||
| Abatacept for the Treatment of Refractory Juvenile Dermatomyositis[NCT02594735] | Phase 4 | 10 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| A Pilot Study of Etanercept in Dermatomyositis[NCT00112385] | Phase 1 | 16 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Treatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEnt[NCT05832034] | Phase 2 | 48 participants (Anticipated) | Interventional | 2021-09-13 | Recruiting | ||
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients[NCT00005571] | Phase 2 | 17 participants | Interventional | 2000-04-30 | Completed | ||
| The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over[NCT00001261] | Phase 2 | 120 participants | Interventional | 1990-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The PRINTO Juvenile Dermatomyositis (JDM) core set variables are:~muscle strength by the mean of the Childhood Myositis Assessment Scale (CMAS);~physician's global assessment of disease activity on a 10 cm Visual Analogue Scale (VAS);~global disease activity assessment by the mean of the Disease Activity Index (DAS);~parent's/patient's global assessment of overall well-being on a 10 cm VAS;~functional ability assessment by the mean of the Childhood Health Assessment Questionnaire (CHAQ)~health-related quality of life assessment." (NCT00323960)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 (MPDN+PDN) | 24 |
| Group 2 (MPDN+PDN+CSA) | 32 |
| Group 3 (MPDN+PDN+MTX) | 33 |
Clinical remission is defined as the status of inactive disease for at least 6 continuous months defined as normal muscle strength (CMAS equal to 52) and physician global assessment of disease activity equal to 0. (NCT00323960)
Timeframe: 60 months
| Intervention | events per 1000 persons-time (Number) |
|---|---|
| Group 1 (MPDN+PDN) | 5.99 |
| Group 2 (MPDN+PDN+CSA) | 4.95 |
| Group 3 (MPDN+PDN+MTX) | 13.39 |
Time to major therapeutic changes is defined as the addition of CSA or MTX or any other disease-modifying antirheumatic drug (DMARS) in any of the 3 groups or discontinuation of assigned therapy for any reason including adverse events. Retention on treatment was used as main measure of effectiveness. (NCT00323960)
Timeframe: 60 months
| Intervention | events per 1000 persons-time (Number) |
|---|---|
| Group 1 (MPDN+PDN) | 30.52 |
| Group 2 (MPDN+PDN+CSA) | 17.52 |
| Group 3 (MPDN+PDN+MTX) | 13.92 |
Prednisone or equivalent glucocorticoid discontinuation is defined as the complete discontinuation of glucocorticoids (NCT00323960)
Timeframe: 60 months
| Intervention | events per 1000 persons-time (Number) |
|---|---|
| Group 1 (MPDN+PDN) | 15.91 |
| Group 2 (MPDN+PDN+CSA) | 27.82 |
| Group 3 (MPDN+PDN+MTX) | 24.42 |
"Patients who have achieved Definition of Improvement (DOI) at week 6 (visit 2) or at any point thereafter and is rated by their study physician as at least minimally improved, then tapering of corticosteroids may commence using a precise dose reduction schedule as follows:~For patients taking 40 to 60 mg daily, prednisone will be tapered by 10 mg ,For patients taking 20 to 35 mg daily, prednisone will be tapered by 5 mg. For patients taking 7.5 to 15 mg daily, prednisone will be tapered by 2.5 mg. For patients taking 1 to 5 mg daily, prednisone will be tapered by 1 mg For patients receiving intravenous pulse methylprednisolone therapy, they may alternatively reduce the dose of IV therapy, instead of oral by a decrease of 25%" (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | mg (Mean) |
|---|---|
| Week 0 (Baseline) | 16.7 |
| Week 24 | 10.2 |
Physical function will be measured by using the Stanford HAQ/CHAQ: Childhood Health Assessment Questionnaire: The Stanford HAQ is a brief self-report questionnaire assessing physical function pertaining to activities of daily living in a variety of domains. The CHAQ was adapted directly from the HAQ and it has also been successfully applied to patients with juvenile myositis, with scores ranging from 0 to 3. Lower scores indicate less physical disability. (NCT02594735)
Timeframe: week 0 to 24
| Intervention | units on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 1.84 |
| Week 24 | 0.88 |
Cutaneous disease activity will be measured using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). CDASI is a clinician-scored instrument that separately measures activity and damage in the skin of dermatomyositis patients for use in clinical practice or clinical/therapeutic studies. Cutaneous disease activity was measured via the activity sub-score of CDASI, ranging from 0-100. Higher scores indicate more disease activity. (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 21.4 |
| Week 24 | 14.0 |
The extramuscular activity will be measured by using the Myositis Disease Activity Assessment Tool (MDAAT). This validated tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0 - 10 cm visual analogue scale (VAS). Extramuscular activity ranges between 0 and 10 via VAS. Lower scores indicate lower disease activity. (NCT02594735)
Timeframe: week 0 to 24
| Intervention | units on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 4.1 |
| Week 24 | 2.4 |
Muscle strength will be measured using an abbreviated Manual Muscle Testing (MMT) in 8 muscles (MMT8) ranging between 0 and 10 for each muscle bilaterally (with the exception of neck flexors, for a total of 15 muscles) with a total score ranging between 0 and 150. Higher scores indicate higher muscle strength. (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 121.8 |
| Week 24 | 137.2 |
"The muscle enzymes include creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). If more than one muscle enzyme is identified as being elevated (a minimum level of 1.3 x the upper limit of normal), then the most abnormal will be selected and this enzyme will be the target enzyme followed to evaluate disease improvement or worsening.~In order to standardize the change in muscle enzymes selected as most abnormal across patients, the outcome measurement was calculated as the most abnormal enzyme level measured via bloodwork divided by the upper limit normal of the healthy reference range (i.e percentage of the upper limit normal for the respective muscle enzyme). Higher percentages indicate higher muscle enzyme levels." (NCT02594735)
Timeframe: week 0 to 24
| Intervention | percentage of upper limit normal (Mean) |
|---|---|
| Week 0 (Baseline) | 1.52 |
| Week 24 | 1.52 |
This tool measures the global evaluation y the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm. visual analogue scale (VAS). Parent/Patient Global Activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to 24
| Intervention | units on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 5.3 |
| Week 24 | 2.3 |
This tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm visual analogue scale (VAS). Physician global activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 5.0 |
| Week 24 | 2.6 |
Axial STIR and T1 MRI images of bilateral thighs and pelvis were obtained at baseline and week 24. Images were coded and reviewed independently by two musculoskeletal radiologists who had comparable inter-observer variability and were blinded to any subject data, including visit number. MRI scoring was performed utilizing a 4-point scale (0-normal, 1-mild, 2-moderate, 3-severe) for muscle edema for each of the muscle groups examined, i.e. gluteal, adductors, hamstrings, and quadriceps, resulting in an aggregate score between 0 to 12. (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Week 0 (Baseline) | 5.3 |
| Week 24 | 2.3 |
"The ACR-EULAR Response Criteria use a continuous total improvement score from baseline (range 0-100) based on the sum of the absolute percent change in the 6 core domains (weighted) used in the IMACS DOI (International Myositis Assessment and Clinical Studies definition of improvement)~IMACS core measures are: Physician Global Assessment of Disease Activity (PGA), Patient (Subject) Global Assessment of Disease Activity (SGA), Manual Muscle Test (MMT-8), Health Assessment Questionnaire-Disability Index (HAQ-DI), Muscle Enzyme levels, Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity.~In children, the total improvement score ranges between 0 and 100 percent corresponds to the degree of improvement, with higher scores corresponding to a greater degree of improvement ( >/= 30 represents minimal improvement, a score of >/= 45 represents moderate improvement, and a score of >/= 75 represents major improvement)." (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Open Label (One Arm) | 53.8 |
Safety will be assessed by review of adverse events using NCI Common Terminology criteria v5.0 November 2017. Particular attention to serious adverse events and infections will be given. An adverse event diary will be maintained throughout the study. Patient evaluations will include: vital sign measurement, physical examination, and laboratory parameters for hematology and routine chemistries (NCT02594735)
Timeframe: week 0 to week 24
| Intervention | events (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Worsening of interstitial lung disease | Compression fracture | Right knee contracture worsening | Worsening calcinosis | Lipoatrophy, focal | Febrile episodes | Skin-infection | E. coli diarrhea | |
| Open Label (One Arm) | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
"The subject's body weight was measured in kilograms(kg). The average value was calculated for each treatment group for the Baseline and Week 52 visits. The average change was determined by subtracting the average value at the Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | Kilograms (Mean) |
|---|---|
| Etanercept | 4.59 |
| Placebo | 3.77 |
"Average change in Cutaneous Disease Activity and Severity Index (CDASI) score from Baseline to Week 52. The assessment graded the severity of the subject's rash. The rash was rated using a a 4-point scale with a score of 0 indicating no rash. The score was added together using all 13 anatomical locations included on the assessment. The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline).~This measure was also collected as part of the study protocol at Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | Units on a scale (Mean) |
|---|---|
| Etanercept | -3.05 |
| Placebo | -0.25 |
"The subject's diastolic blood pressure was measured in millimeters of mercury (mm Hg). The average value was calculated for the Baseline and Week 52 visit based on treatment group. The average change was determined by subtracting the average value Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4,8,12,16,20,24,32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | mmHg (Mean) |
|---|---|
| Etanercept | -6.10 |
| Placebo | 1.00 |
"The subject's oral temperature was measured in degrees Celsius. The average change was determined by subtracting the Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4,8,12,16,20,24,32 and 40." (NCT00112385)
Timeframe: At Baseline (Week 0) and Week 52
| Intervention | degrees Celsius (Mean) |
|---|---|
| Etanercept | 0.16 |
| Placebo | 0.20 |
"Average change in Patient Global Activity Assessment score from Baseline to Week 52. The assessment used a Visual Analog Scale to rate the subject's perceived global (overall) disease activity. A score of 0 cm indicated no evidence of disease activity. A score of 10.0 cm indicated extremely active disease.~This measure was also collected as part of the study protocol at Week 12, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | cm (Mean) |
|---|---|
| Etanercept | -2.34 |
| Placebo | -0.38 |
"Average change in percent predicted Diffusion Capacity (DLCO)from the Screening Visit to Week 52 was calculate. The average change was determined by subtracting the Screening test results from the Week 52 results (Week 52- Screening Visit). The Screening visit occurred within 8 weeks prior to the Baseline visit.~This assessment was also completed during the Week 24 visit." (NCT00112385)
Timeframe: Screening visit and Week 52
| Intervention | Percent predicted (Mean) |
|---|---|
| Etanercept | -4.50 |
| Placebo | -14.67 |
"The average change in percent predicted Forced Expiratory Volume in 1 second (FEV1) from Screening to Week 52 was calculated. The average change was determined by subtracting the Screening Visit results from the Week 52 results (Week 52- Screening visit). The Screening visit occurred within 8 weeks prior to the Baseline visit.~This assessment was also completed during the Week 24 visit." (NCT00112385)
Timeframe: Screening Visit and Week 52
| Intervention | Percent predicted (Mean) |
|---|---|
| Etanercept | -0.67 |
| Placebo | -4.25 |
"Average change in Physician Global Activity Assessment score from Baseline to Week 52. The assessment used a Visual Analog Scale to rate the subject's global (overall) disease activity. A score of 0 cm indicated no evidence of disease activity. A score of 10.0 cm indicated extremely active disease. The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline).~This measure was also collected as part of the study protocol at Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | cm (Mean) |
|---|---|
| Etanercept | -2.36 |
| Placebo | -1.32 |
"The subject's pulse was measured in beats per minute (BPM). The average value was calculated per treatment group for the Baseline and Week 52 visit. The average change was determined by subtracting the average value Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | beats per minute (Mean) |
|---|---|
| Etanercept | -4.40 |
| Placebo | -7.25 |
"The subject's respiration rate was measured as number of breaths per minute. The average change was determined by subtracting the Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4,8,12,16,20,24,32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | breaths per minute (Mean) |
|---|---|
| Etanercept | -2.44 |
| Placebo | -2.00 |
"The subject's systolic blood pressure was measured in millimeters of mercury (mmHg). The average value was calculated per treatment group for the Baseline and Week 52 visit based on treatment group. The average change was determined by subtracting the average value Baseline Visit (Week 0) results from the Week 52 results (Week 52- Baseline (Week 0)).~This measure was also collected as part of the study protocol at the Screening visit and Week 4,8,12,16,20,24,32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | mmHg (Mean) |
|---|---|
| Etanercept | -13.3 |
| Placebo | -3.0 |
"Average change in time to walk 30 feet comparing Baseline performance to Week 52.The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline).~This measure was also collected as part of the study protocol at Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | Seconds (Mean) |
|---|---|
| Etanercept | -2.26 |
| Placebo | -0.55 |
"The Average change in time to rise from a chair comparing Baseline performance to Week 52.The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline).~This measure was also collected as part of the study protocol at Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | Seconds (Mean) |
|---|---|
| Etanercept | -.05 |
| Placebo | -1.22 |
"The average change in z-score for Dual-emission X-ray absorptiometry (DEXA) of the femur from the Screening visit to the Week 52 visit was calculated. The average change was determined by subtracting the Screening Visit test results from the Week 52 results (Week 52- Screening visit).~The Screening visit was conducted within 8 weeks of the Baseline visit." (NCT00112385)
Timeframe: Screening and Week 52
| Intervention | Z-score (Mean) |
|---|---|
| Etanercept | 0.17 |
| Placebo | -0.57 |
The average change in z-score for Dual-emission X-ray absorptiometry (DEXA) of the lumbar spine was calculated comparing the results from the Screening visit to Week 52. The average change was determined by subtracting the Screening Visit (Week <8)test results from the Week 52 results (Week 52- screening Visit). The Screening visit occurred within 8 weeks of the Baseline visit. (NCT00112385)
Timeframe: Screening visit and Week 52.
| Intervention | Z-Score (Mean) |
|---|---|
| Etanercept | -0.10 |
| Placebo | 0.07 |
The average cumulative dosage of prednisone over the one year period of the study was calculated. The results are presented by treatment group. (NCT00112385)
Timeframe: Baseline until week 52
| Intervention | mg (Mean) |
|---|---|
| Etanercept | 5907.09 |
| Placebo | 9917.65 |
The average daily dose of prednisone from baseline to week 52 was calculated by treatment group. (NCT00112385)
Timeframe: Baseline through Week 52
| Intervention | mg (Mean) |
|---|---|
| Etanercept | 17.00 |
| Placebo | 36.40 |
We calculated the average dosage of prednisone from the week 24 visit until the end of the study (week 52). (NCT00112385)
Timeframe: from week 24 to 52
| Intervention | mg (Median) |
|---|---|
| Etanercept | 1.2 |
| Placebo | 29.2 |
"The Health Assessment Questionnaire (HAQ)was completed by subjects to assess the affects of their illness on the ability to function in daily life. The HAQ consists of 8 sections. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).The 8 scores of the 8 sections are summed and divided by 8. A higher score indicates more impairment.~The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline).~This measure was also collected as part of the study protocol at Week 12, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0) and Week 52
| Intervention | Units on a scale (Mean) |
|---|---|
| Etanercept | -0.33 |
| Placebo | -0.34 |
"This is the average change in pruritis score from Baseline to Week 52. The assessment used a Visual Analog Scale to rate the subject's perceived level of pruritis (itchiness). A score of 0 cm indicated Not itchy at all. A score of 10.0 cm indicated Extremely itchy.~This assessment was also completed at Week 4, 8, 12, 16, 20, 24, 32 and 40." (NCT00112385)
Timeframe: At Baseline (Week0), and Week 52
| Intervention | cm (Mean) |
|---|---|
| Etanercept | 0.33 |
| Placebo | -1.64 |
"The Manual Muscle Test (MMT) assesses 26 muscle groups. The muscle strength of each muscle group is graded. The score for each muscle group ranges from 0 (No contraction palpable) to 5 (normal strength). The minimum total MMT score is a 0. The maximum total MMT score is a 130.~The average change in the average Manual Muscle Testing (MMT)from Baseline to Week 52 was calculated. The average score is composed of 26 muscle groups that were tested. The average change was determined by subtracting the Baseline test results from the Week 52 results (Week 52- Baseline)." (NCT00112385)
Timeframe: At Baseline (Week 0) and Week 52
| Intervention | Units on a scale (Mean) |
|---|---|
| Etanercept | 0.24 |
| Placebo | 0.30 |
"The average change in percent predicted Forced Vital Capacity (FVC) from the Screening Visit to Week 52 was calculated. The average change was determined by subtracting the Screening Visit results from the Week 52 results (Week 52- Screening Visit). The Screening visit occurred within 8 weeks prior to the Baseline visit.~This assessment was also completed at the Week 24 visit." (NCT00112385)
Timeframe: Screening Visit and Week 52.
| Intervention | Percent predicted (Mean) |
|---|---|
| Etanercept | -2.56 |
| Placebo | -1.00 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not. A subject was considered to have a treatment emergent, clinically significant ALT value if during the course of the study, they had at least one clinically significant ALT result that was not present at baseline.~Subjects had ALT labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 1 |
| Placebo | 1 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant Aldolase value if during the course of the study, they had at least one clinically significant Aldolase result that was not present at baseline. Subjects had Aldolase labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: Screening, Baseline (Week0), Week 4, 8,12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 1 |
| Placebo | 2 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant Antinuclear Antibody Test (ANA) result that was not present at baseline. Subjects had ANA labs collected at Screening, Week 12, 24, 40, and 52." (NCT00112385)
Timeframe: At Screening, Week 12, 24, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 1 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant creatine kinase (CK) value if during the course of the study, they had at least one clinically significant CK result that was not present at baseline. Subjects had CK labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 1 |
| Placebo | 2 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant GGT value if during the course of the study, they had at least one clinically significant GGT result that was not present at baseline. Subjects had GGT labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 1 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant Glucose value if during the course of the study, they had at least one clinically significant Glucose result that was not present at baseline. Subjects had Glucose labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 1 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant hematocrit value if during the course of the study, they had at least one clinically significant hematocrit result that was not present at baseline. Subjects had hematocrit labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant Hemoglobin value if during the course of the study, they had at least one clinically significant Hemoglobin result that was not present at baseline. Subjects had hemoglobin labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant monoclonal protein value that was not present at baseline. Subjects had monoclonal protein labs collected at Screening, Week 12, 24, 40, and 52." (NCT00112385)
Timeframe: Screening visit, Week 12, 24, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant platelet value if during the course of the study, they had at least one clinically significant platelet result that was not present at baseline. Subjects had platelet labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant Potassium value if during the course of the study, they had at least one clinically significant Potassium result that was not present at baseline. Subjects had Potassium labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant serum 25-hydroxyvitamin D (25-OH VitD) result that was not present at baseline. Subjects had 25-OH VitD labs collected at Screening and at the Week 52 visit." (NCT00112385)
Timeframe: Screening visit and Week 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant urine glucose result that was not present at baseline. Subjects had urine glucose labs collected at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 1 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant urine ketone result that was not present at baseline. Subjects had urine ketone labs collected at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least 1 clinically significant urine leukocyte result that was not present at baseline. Subjects had urine leukocyte labs collected at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 0 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant value if during the course of the study, they had at least one clinically significant urine protein result that was not present at baseline. Subjects had urine protein labs collected at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: At Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 1 |
| Placebo | 1 |
"The site investigators used the reference ranges provided by the lab that completed the testing of the sample to determine if the value was abnormal. If a value was abnormal, the site investigator would determine if the value was clinically significant or not.~A subject was considered to have a treatment emergent, clinically significant White Blood Cell (WBC) value if during the course of the study, they had at least one clinically significant WBC result that was not present at baseline. Subjects had WBC labs drawn at Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52." (NCT00112385)
Timeframe: Screening, Baseline (Week0), Week 4, 8, 12, 16, 20, 24, 32, 40, and 52
| Intervention | participants (Number) |
|---|---|
| Etanercept | 0 |
| Placebo | 1 |
Treatment failures were determined based on criteria from the study protocol using objective and subjective ratings from the study physician. If the study physician felt that the rate of prednisone taper needed to be reduced, the prednisone dose needed to be increased or restarted, or a second-line agent added, the patient will be considered to be a treatment failure. (NCT00112385)
Timeframe: At any point during the 52 week study
| Intervention | participants (Number) |
|---|---|
| Etanercept | 6 |
| Placebo | 5 |
The reported tolerability measure was defined as the number of participants that completed the entire 52 week study on their originally assigned treatment. (NCT00112385)
Timeframe: At any point between Baseline (week 0) and the end of the study (Week 52)
| Intervention | Participants (Number) |
|---|---|
| Etanercept | 10 |
| Placebo | 4 |
"Adverse events (AEs) were assessed using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). The grade of mild, moderate or severe matches with the descriptions from the CTCAE dictionary.~In general, a Mild AE is asymptomatic; clinical or diagnostic observations only; intervention not indicated.~A Moderate AE is minimal, local or noninvasive intervention indicated; limiting activities of daily living.~A Severe AE is medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling;" (NCT00112385)
Timeframe: at each visit during the 12 month study
| Intervention | participants (Number) | ||
|---|---|---|---|
| Mild AE | Moderate AE | Severe AE | |
| Etanercept | 1 | 5 | 5 |
| Placebo | 1 | 1 | 3 |
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| Group A | -9 |
| Group B | 12 |
44 reviews available for prednisone and Dermatomyositis, Adult Type
| Article | Year |
|---|---|
Dilemma in management of hemorrhagic myositis in dermatomyositis.
Topics: Compression Bandages; Conservative Treatment; Dermatomyositis; Drainage; Enzyme Inhibitors; Female; | 2020 |
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.
Topics: Anti-Inflammatory Agents; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Lung Diseases, | 2017 |
Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies.
Topics: Adult; Autoimmune Diseases; Biomarkers; Brazil; Dermatomyositis; Exercise; Exercise Therapy; Glucoco | 2019 |
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
Topics: Anti-Inflammatory Agents; Autoantibodies; Child; Cyclosporine; Dermatomyositis; Humans; Immunoglobul | 2013 |
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Cohort Studies; Derm | 2014 |
Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature.
Topics: Aged; Aged, 80 and over; Dermatomyositis; Edema; Fatal Outcome; Female; Humans; Immunoglobulins, Int | 2014 |
Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Topics: Adult; Aged; Autoantibodies; Dermatomyositis; Disease Progression; Female; Glucocorticoids; Humans; | 2016 |
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.
Topics: Child; Child, Preschool; Dermatomyositis; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Myo | 2008 |
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.
Topics: Child; Child, Preschool; Dermatomyositis; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Myo | 2008 |
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.
Topics: Child; Child, Preschool; Dermatomyositis; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Myo | 2008 |
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.
Topics: Child; Child, Preschool; Dermatomyositis; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Myo | 2008 |
Dermatomyositis and HIV infection: case report and review of the literature.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Autoimmunity; Biopsy; Dermatomyositis | 2011 |
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Derma | 2011 |
Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis.
Topics: Anti-Inflammatory Agents; Dermatologic Agents; Dermatomyositis; Drug Therapy, Combination; Female; H | 2004 |
Renal failure in a patient with autosomal dominant polycystic kidney disease and coexisting dermato-polymyositis: first report in the literature.
Topics: Dermatomyositis; Glucocorticoids; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; | 2004 |
Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate.
Topics: Biopsy; Brain Neoplasms; Burkitt Lymphoma; Dermatomyositis; Humans; Immunosuppressive Agents; Magnet | 2004 |
Fatal acute fibrinous and organizing pneumonia in a child with juvenile dermatomyositis.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Dermatomyo | 2005 |
Acute dermatomyositis with subcutaneous generalized edema.
Topics: Acute Disease; Adult; Dermatomyositis; Disease Progression; Edema; Fatal Outcome; gamma-Globulins; H | 2006 |
[Juvenile dermatomyositis].
Topics: Adolescent; Biopsy; Child; Child, Preschool; Combined Modality Therapy; Dermatomyositis; Diagnosis, | 2006 |
Pulmonary disease in polymyositis/dermatomyositis.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Dermatomyositis; Female; Humans; Immunosuppressive Agents | 1984 |
The specificity and clinical usefulness of the lupus band test.
Topics: Antibodies, Antinuclear; Antigen-Antibody Complex; Arthritis, Rheumatoid; Basement Membrane; Blood V | 1980 |
Polymyositis-dermatomyositis and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 1993 |
[Spontaneous hemothorax in dermatomyositis and long-term glucocorticoid treatment].
Topics: Aged; Bronchopneumonia; Dermatomyositis; Fatal Outcome; Female; Hemothorax; Humans; Pleural Effusion | 1995 |
[Dermatomyositis in childhood with recurrence in adulthood: 2 cases].
Topics: Adult; Age Factors; Alopecia Areata; Atrophy; Child; Child, Preschool; Dermatomyositis; Female; Huma | 1993 |
Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
Topics: Adult; Aged; Antirheumatic Agents; Cyclosporine; Dermatomyositis; Female; Humans; Immunosuppressive | 2000 |
Dermatomyositis.
Topics: Adult; Azathioprine; Child; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Female; H | 2001 |
Panniculitis: a cutaneous manifestation of dermatomyositis.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Dermatomyositis; Female; Follow-Up Studies; Humans; | 2002 |
Dermatomyositis of childhood.
Topics: Adolescent; Biopsy; Child; Child, Preschool; Dermatomyositis; Female; Humans; Infant; Male; Muscles; | 1977 |
The spectrum of polymyositis and dermatomyositis.
Topics: Adolescent; Adult; Child; Dermatomyositis; Electromyography; Female; Humans; Immunosuppressive Agent | 1977 |
Dermatomyositis: a vocal and swallowing disease entity.
Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Deglutition Disorders; Dermatomyositis; D | 1978 |
[Treatment of myopathies and spinal muscular atrophies (author's transl)].
Topics: Amyotrophic Lateral Sclerosis; Azathioprine; Collagen Diseases; Dermatomyositis; Glycogen Storage Di | 1978 |
[Polymyositis].
Topics: Antineoplastic Agents; Child; Dermatomyositis; Enzymes; Humans; Immunosuppression Therapy; Methotrex | 1976 |
Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature.
Topics: Dermatomyositis; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Myositis; Photosensitiv | 1991 |
[Interstitial pulmonary involvement of polymyositis and dermatomyositis. Apropos of 3 cases. Review of the literature].
Topics: Adult; Antibodies, Antinuclear; Bronchoalveolar Lavage Fluid; Dermatomyositis; Female; Humans; Male; | 1991 |
Primary idiopathic polymyositis and dermatomyositis complicating pregnancy: diagnosis and management.
Topics: Adult; Dermatomyositis; Female; Humans; Myositis; Prednisone; Pregnancy; Pregnancy Complications | 1989 |
Dermatomyositis.
Topics: Abortion, Spontaneous; Dermatomyositis; Female; Fetal Death; Humans; Prednisone; Pregnancy; Pregnanc | 1989 |
[Treatment of polymyositis and dermatomyositis].
Topics: Dermatomyositis; Humans; Myositis; Plasma Exchange; Prednisolone; Prednisone | 1989 |
Treatment of polymyositis and dermatomyositis.
Topics: Adrenal Cortex Hormones; Dermatomyositis; Humans; Immunosuppressive Agents; Muscular Diseases; Myosi | 1989 |
Inflammatory myopathies: Part 2.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antinuclear; Cytomegalovirus Infections; Dermatomyositis | 1985 |
[Polymyositis and dermatomyositis in childhood].
Topics: Adolescent; Calcinosis; Child; Child, Preschool; Dermatomyositis; Female; Follow-Up Studies; Humans; | 1988 |
Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.
Topics: Adult; Azathioprine; Cyclosporins; Dermatomyositis; Drug Resistance; Female; Humans; Myositis; Predn | 1987 |
Treatment of muscular dystrophies and inflammatory myopathies.
Topics: Azathioprine; Clinical Trials as Topic; Dermatomyositis; Humans; Muscular Dystrophies; Myositis; Myo | 1986 |
[Drug therapy in collagen diseases].
Topics: Adenosine Triphosphatases; Administration, Oral; Adrenal Cortex Hormones; Antimalarials; Antineoplas | 1971 |
Adrenal steroid therapy in neurological disease. Part I.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Arteritis; Arthritis, Rheumatoid; Col | 1969 |
[Collagen diseases].
Topics: Acute Kidney Injury; Antineoplastic Agents; Biopsy; Collagen Diseases; Corpus Luteum Hormones; Derma | 1969 |
Polymyositis: new light on pathogenesis and treatment.
Topics: Adult; Antilymphocyte Serum; Autoimmune Diseases; Dermatomyositis; Humans; Immunosuppressive Agents; | 1973 |
Dermatomyositis.
Topics: Adrenal Cortex Hormones; Animals; Child; Dermatomyositis; Diagnosis, Differential; Enzymes; Follow-U | 1973 |
13 trials available for prednisone and Dermatomyositis, Adult Type
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.
Topics: Adult; Cross-Over Studies; Dermatologic Agents; Dermatomyositis; Double-Blind Method; Drug Administr | 2018 |
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Child; Child, Preschool; Cyclosporine; Dermatologic | 2019 |
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
Topics: Adolescent; Analysis of Variance; Anti-Inflammatory Agents; Child; Child, Preschool; Cyclosporine; D | 2016 |
A randomized, pilot trial of etanercept in dermatomyositis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositi | 2011 |
Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
Topics: Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antirheumatic Agents; Creatine Kinase; | 2004 |
Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
Topics: Administration, Oral; Adolescent; Alendronate; Arthritis, Juvenile; Body Height; Bone Density; Bone | 2005 |
The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.
Topics: Dermatomyositis; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedu | 2005 |
Systemic lupus erythematosus--corticosteroids.
Topics: Adrenal Cortex Hormones; Central Nervous System Diseases; Clinical Trials as Topic; Dermatomyositis; | 1983 |
Cyclosporine A as first choice therapy for dermatomyositis.
Topics: Adult; Aged; Azathioprine; Cyclosporine; Dermatomyositis; Drug Therapy, Combination; Female; Humans; | 1994 |
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Topics: Adolescent; Adult; Dermatomyositis; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunogl | 1993 |
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Topics: Adolescent; Adult; Dermatomyositis; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunogl | 1993 |
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Topics: Adolescent; Adult; Dermatomyositis; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunogl | 1993 |
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Topics: Adolescent; Adult; Dermatomyositis; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunogl | 1993 |
A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Topics: Adult; Aged; Anti-Inflammatory Agents; Dermatomyositis; Edema; Female; Flow Cytometry; Hematologic T | 1999 |
The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Biopsy; Creatine Kinase; Dermatomyositis; Exercise | 2000 |
Treatment of muscular dystrophies and inflammatory myopathies.
Topics: Azathioprine; Clinical Trials as Topic; Dermatomyositis; Humans; Muscular Dystrophies; Myositis; Myo | 1986 |
308 other studies available for prednisone and Dermatomyositis, Adult Type
| Article | Year |
|---|---|
Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Topics: Abatacept; Adolescent; Arthritis; Autoantibodies; Azathioprine; Calcinosis; Child; Cyclophosphamide; | 2022 |
COVID-19 quarantine in adolescents with autoimmune rheumatic diseases: mental health issues and life conditions.
Topics: Adolescent; Arthritis, Juvenile; Child; COVID-19; Cross-Sectional Studies; Dermatomyositis; Female; | 2022 |
Diffuse large B-cell lymphoma in a patient with dermatomyositis-associated interstitial lung disease: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Dermatomyositis; Doxorubic | 2019 |
Concomitant cerebral aspergillosis and mucormycosis in an immunocompetent woman treated with corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Brain Diseases; Coinfection; Dermatomyositis; Fem | 2020 |
Mesenteric panniculitis in a patient with new onset dermatomyositis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Dermatomyositis; Female; Humans; Mycophenolic Acid; Pan | 2020 |
Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease.
Topics: Autoantibodies; Computed Tomography Angiography; Dermatomyositis; Diagnosis, Differential; Disease P | 2020 |
Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis.
Topics: Adult; Azathioprine; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Prednisone; Rituxim | 2021 |
Autoimmune Conditions: Polymyalgia Rheumatica and Dermatomyositis.
Topics: Dermatomyositis; Diagnosis, Differential; Giant Cell Arteritis; Glucocorticoids; Humans; Polymyalgia | 2020 |
A case of Wong-type dermatomyositis treated with rituximab and IVIG.
Topics: Adult; Dermatomyositis; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunoglobulins, | 2021 |
Cricoarytenoid joint arthritis: a possible complication of dermatomyositis.
Topics: Adult; Arthritis; Arytenoid Cartilage; Cricoid Cartilage; Dermatomyositis; Female; Glucocorticoids; | 2020 |
MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin.
Topics: Adrenal Cortex Hormones; Adult; Dermatomyositis; Female; Glucocorticoids; Humans; Immunoglobulins, I | 2020 |
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Antifungal Agents; Dermatomyositis; Drug Admi | 2020 |
Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study.
Topics: Adult; Bone Density Conservation Agents; Calcinosis; Cohort Studies; Dermatomyositis; Diphosphonates | 2021 |
Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
Topics: Adult; Aged; Alanine-tRNA Ligase; Antibodies, Antinuclear; Autoantibodies; China; Cohort Studies; De | 2021 |
Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences.
Topics: Adolescent; Analgesics; Antirheumatic Agents; Child; Dermatomyositis; Female; Fractures, Bone; Fract | 2021 |
The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis.
Topics: Adult; Age Factors; Antibodies, Antinuclear; Autoantibodies; Dermatomyositis; Female; Glucocorticoid | 2021 |
A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; C | 2021 |
Multicentric reticulohistiocytosis masquerading as cutaneous connective tissue disease.
Topics: Aged, 80 and over; Connective Tissue Diseases; Dermatologic Agents; Dermatomyositis; Diagnosis, Diff | 2021 |
Widespread poikilodermatous dermatomyositis associated with chronic lymphocytic leukemia.
Topics: Abdomen; Antineoplastic Agents, Immunological; Arm; Back; Dermatomyositis; Diagnosis, Differential; | 2017 |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology Inter
Topics: Adolescent; Alanine Transaminase; Antirheumatic Agents; Aspartate Aminotransferases; Child; Creatine | 2017 |
Primary Cutaneous Aggressive Epidermotropic CD8+ T-cell Lymphoma with Brain Involvement and Mimicking Dermatomyositis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Brain Neoplas | 2018 |
Wong-type dermatomyositis: A first report from Japan.
Topics: Dermatomyositis; Diagnosis, Differential; Fatal Outcome; Female; Glucocorticoids; Humans; Japan; Mid | 2017 |
Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.
Topics: Adolescent; Child; Child, Preschool; Dermatomyositis; Female; Glucocorticoids; Hospitalization; Huma | 2017 |
Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody.
Topics: Anti-Inflammatory Agents; Autoantibodies; Dermatomyositis; Humans; Interferon-Induced Helicase, IFIH | 2018 |
Wong-Type Dermatomyositis Complicated by Interstitial Lung Disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Dermatomyositis; Diagnosis, Different | 2018 |
Koebner Phenomenon in Juvenile Dermatomyositis.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Creatine Kinase; Dermatologic Ag | 2018 |
Medications received by patients with juvenile dermatomyositis.
Topics: Adolescent; Age Factors; Age of Onset; Antimalarials; Autoantibodies; Child; Child, Preschool; Derma | 2018 |
Evaluating results of an interferon-γ release assay in patients with autoimmune disease who are taking hydroxychloroquine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Dermatomyositis; Female; Humans; Hydrox | 2019 |
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
Topics: Adult; Antirheumatic Agents; Dermatomyositis; Drug Administration Schedule; Female; Glucocorticoids; | 2018 |
Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series.
Topics: Autoimmune Diseases; Dermatomyositis; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Im | 2018 |
A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Topics: Adult; Azathioprine; Cyclophosphamide; Dermatomyositis; Drug Administration Schedule; Drug Resistanc | 2013 |
Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Cohort Studies; Dermatomyositis; Dose-Resp | 2013 |
Dermatomyositis panniculitis: a case report.
Topics: Anti-Inflammatory Agents; Cyclophosphamide; Dermatomyositis; Drug Therapy, Combination; Female; Huma | 2015 |
Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.
Topics: Adolescent; Antirheumatic Agents; Child; Child, Preschool; Dermatomyositis; Disease Progression; Dru | 2014 |
Increased levels of HSPA5 in the serum of patients with inflammatory myopathies--preliminary findings.
Topics: Adult; Aged; Creatine Kinase; Dermatomyositis; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperon | 2015 |
Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.
Topics: Anti-Inflammatory Agents; Creatine Kinase; Dermatomyositis; Disease Progression; Female; Humans; Imm | 2015 |
Paraneoplastic Dermatomyositis Accompanying Nasopharyngeal Carcinoma.
Topics: Carcinoma; Dermatomyositis; Dexamethasone; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Naso | 2015 |
Progress in the treatment of juvenile dermatomyositis.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Dermatomyositis; Female; Humans; Male; | 2016 |
Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness.
Topics: Colectomy; Colon; Colonic Diseases; Dermatomyositis; Female; Glucocorticoids; Humans; Immunoglobulin | 2016 |
Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Prolife | 2016 |
Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
Topics: Child, Preschool; Dermatomyositis; Female; Glucocorticoids; Humans; Immunoglobulins; Immunoglobulins | 2016 |
A patient with muscle weakness.
Topics: Adult; Anti-Inflammatory Agents; Dermatomyositis; Female; Humans; Muscle Weakness; Prednisone | 2016 |
Primary thyroid lymphoma presenting as dermatomyositis: a first case and review of the literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
[Panniculitis in patient undergoing treatment for dermatomyositis with methotrexate].
Topics: Dermatologic Agents; Dermatomyositis; Dose-Response Relationship, Drug; Drug Therapy, Combination; F | 2016 |
The PRINTO juvenile dermatomyositis trial.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Dermatomyositis; Female; Humans; Male; | 2016 |
The PRINTO juvenile dermatomyositis trial - Authors' reply.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Dermatomyositis; Female; Humans; Male; | 2016 |
Digital Pulp Ulcerations and Inverse Gottron Papules in Melanoma Differentiation-Associated Gene 5-Related Dermatomyositis.
Topics: Antibodies; Dermatomyositis; Fingers; Humans; Immunosuppressive Agents; Interferon-Induced Helicase, | 2016 |
Abnormal wound healing related to high-dose systemic corticosteroid therapy in a patient with Ehlers-Danlos syndrome benign hypermobility Type.
Topics: Dermatomyositis; Ehlers-Danlos Syndrome; Elbow; Glucocorticoids; Hand Dermatoses; Humans; Knee; Male | 2016 |
The Use of Rituximab in the Management of Refractory Dermatomyositis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Dermatomyositis; Drug-Related Side Effects and Advers | 2017 |
[Autoimmune myelofibrosis with dermatomyositis].
Topics: Adult; Anti-Inflammatory Agents; Autoimmune Diseases; Biopsy; Dermatologic Agents; Dermatomyositis; | 2009 |
The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis.
Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Dermatomyositis; Dose-Response Relationship, Drug | 2008 |
[Juvenile dermatomyositis: 4 case studies].
Topics: Child; Child, Preschool; Dermatomyositis; Female; Glucocorticoids; Humans; Infant; Male; Prednisone | 2008 |
Severe erosive arthropathy requiring surgical treatments in systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Arthritis; Arthroplasty, Replacement, Hip; Cysts; Dermatomyositis; | 2009 |
[Therapeutic strategies in idiopatic inflammatory myopathies].
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Biopsy; Dermatomyos | 2009 |
Dermatomyositis with inclusion body myositis pathology.
Topics: Anti-Inflammatory Agents; Antigens, CD; Dermatologic Agents; Dermatomyositis; Humans; Male; Methotre | 2009 |
Development of classic dermatomyositis rash years after diagnosis of juvenile polymyositis.
Topics: Anti-Inflammatory Agents; Child; Dermatomyositis; Disease Progression; Drug Therapy, Combination; Ex | 2009 |
A case of dermatomyositis with "liver disease associated with rheumatoid diseases" positive for anti-liver-kidney microsome-1 antibody.
Topics: Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Comorbidity; Dermatomyositis; Female; Humans; Kid | 2010 |
Evolution of clinically amyopathic dermatomyositis despite aggressive immunosuppression with cyclophosphamide and prednisone.
Topics: Cyclophosphamide; Dermatomyositis; Disease Progression; Humans; Immunosuppressive Agents; Lung Disea | 2010 |
Early-stage testicular cancer: a rare association with dermatomyositis.
Topics: Adult; Dermatologic Agents; Dermatomyositis; Glucocorticoids; Humans; Male; Methotrexate; Neoplasms, | 2010 |
Neuroendocrine pancreatic tumor and dermatomyositis.
Topics: Adult; Blood Glucose; Cell Proliferation; Creatine Kinase; Dermatomyositis; Female; Humans; Neuroend | 2010 |
Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis.
Topics: Aged; Antirheumatic Agents; Area Under Curve; Cyclosporine; Dermatomyositis; Drug Monitoring; Drug T | 2011 |
Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.
Topics: Adult; Aged; Dermatomyositis; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunoglobulins; I | 2011 |
Dermatomyositis with anti-OJ antibody.
Topics: Autoantibodies; Cyclosporine; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Immunosupp | 2011 |
A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem.
Topics: Anti-Inflammatory Agents; Calcinosis; Calcium Channel Blockers; Child; Dermatomyositis; Diltiazem; D | 2011 |
Annular lichen myxedematosus in a patient with dermatomyositis.
Topics: Biopsy; Dermatomyositis; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Scleromyxedema; Ski | 2011 |
Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; Dermatomyositis; Drug Therap | 2011 |
PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators.
Topics: Chemoprevention; Dermatomyositis; Humans; Inflammation Mediators; Lymphopenia; Male; Middle Aged; Op | 2011 |
Multicentric reticulohistiocytosis with elevated cytokine serum levels.
Topics: Aged; Cytokines; Dermatomyositis; Histiocytosis, Non-Langerhans-Cell; Humans; Male; Methotrexate; Pr | 2011 |
Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.
Topics: Administration, Intravenous; Administration, Oral; Adrenal Cortex Hormones; Adult; Azathioprine; Coh | 2012 |
Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis.
Topics: Biopsy, Needle; Child; Dermatomyositis; Diagnosis, Differential; Follow-Up Studies; Humans; Immunohi | 2012 |
Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin.
Topics: Adult; Anti-Inflammatory Agents; Calcinosis; Dermatomyositis; Female; Humans; Immunoglobulins, Intra | 2012 |
Co-occurrence of dermatomyositis and Hashimoto's thyroiditis in a type I diabetic patient.
Topics: Dermatomyositis; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucocorticoids; Hash | 2015 |
Dysphonia and dermatomyositis: an unusual manifestation.
Topics: Adult; Antirheumatic Agents; Biopsy; Dermatomyositis; Diagnosis, Differential; Drug Therapy, Combina | 2013 |
Dermatomyositis in two siblings and a brief review of familial dermatomyositis.
Topics: Child, Preschool; Dermatomyositis; Female; Glucocorticoids; Humans; Male; Prednisone; Siblings; Trea | 2002 |
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
Topics: Calcinosis; Child; Child, Preschool; Dermatomyositis; Female; Glucocorticoids; Humans; Male; Methotr | 2002 |
Dermatomyositis with normal creatine kinase and elevated aldolase levels.
Topics: Adult; Aspartate Aminotransferases; Creatine Kinase; Dermatomyositis; Fructose-Bisphosphate Aldolase | 2002 |
[Expression of apoptosis of the skin lesion and muscle from patients with dermatomyositis].
Topics: Adult; Anti-Inflammatory Agents; Apoptosis; Dermatomyositis; fas Receptor; Female; Humans; Male; Mid | 2001 |
Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; | 2003 |
Myokymia, neuromyotonia, dermatomyositis, and voltage-gated K+ channel antibodies.
Topics: Action Potentials; Adult; Autoantibodies; Cyclophosphamide; Dermatomyositis; Facial Nerve Diseases; | 2003 |
Periorbital edema as the presenting sign of dermatomyositis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Dermatomyositis; Diagnosis, Differe | 2003 |
Juvenile dermatomyositis in a 28-month-old infant.
Topics: Anti-Inflammatory Agents; Child, Preschool; Dermatomyositis; Female; Humans; Infant; Prednisone; Rad | 2003 |
Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Carcinoma, Squamous Cell; Combin | 2003 |
Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis.
Topics: Antibodies, Antinuclear; Dermatomyositis; Fatal Outcome; Glucocorticoids; Humans; Immunosuppressive | 2003 |
[Value of corticotherapy and its progress in the treatment of dermatomyositis].
Topics: Cortisone; Dermatomyositis; Humans; Hydrocortisone; Prednisone | 1956 |
[Value of corticotherapy and its progress in the treatment of dermatomyositis].
Topics: Cortisone; Dermatomyositis; Humans; Hydrocortisone; Prednisone | 1956 |
[Value of corticotherapy and its progress in the treatment of dermatomyositis].
Topics: Cortisone; Dermatomyositis; Humans; Hydrocortisone; Prednisone | 1956 |
[Value of corticotherapy and its progress in the treatment of dermatomyositis].
Topics: Cortisone; Dermatomyositis; Humans; Hydrocortisone; Prednisone | 1956 |
[A case of acute systemic lupus erythematosus with extensive muscle atrophy; necessity of differentiation from dermatomyositis; positive effect of therapy with prednisone and nivaquine].
Topics: Cell Differentiation; Chloroquine; Dermatomyositis; Humans; Lupus Erythematosus, Systemic; Muscular | 1958 |
Dermatomyositis successfully treated by prednisone.
Topics: Dermatomyositis; Humans; Prednisone | 1958 |
[Prednisone and dexamethasone in the treatment of dermatomyositis].
Topics: Dermatomyositis; Dexamethasone; Humans; Prednisolone; Prednisone | 1960 |
[A case of chronic dermatomyositis treated with prednisone].
Topics: Dermatomyositis; Humans; Prednisone | 1960 |
DERMATOMYOSITIS.
Topics: Biopsy; Clinical Laboratory Techniques; Dermatomyositis; Electrocardiography; Electromyography; Huma | 1963 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
PATTERNS OF POLYMYOSITIS AND THEIR RESPONSES TO TREATMENT.
Topics: Adolescent; Alanine Transaminase; Antacids; Aspartate Aminotransferases; Child; Clinical Enzyme Test | 1963 |
[GENERAL CORTICOTHERAPY IN DERMATOLOGY].
Topics: Adrenal Cortex Hormones; Cortisone; Dermatitis Herpetiformis; Dermatology; Dermatomyositis; Dexameth | 1963 |
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF SERUM ENZYMES. II. NEUROLOGIC DISEASES OTHER THAN MUSCULAR DYSTROPHY.
Topics: Adenosine Triphosphatases; Alanine Transaminase; Arthritis; Arthritis, Rheumatoid; Aspartate Aminotr | 1964 |
THREE TYPES OF PULMONARY INVOLVEMENT IN POLYMYOSITIS.
Topics: Adrenocorticotropic Hormone; Anti-Bacterial Agents; Aspartate Aminotransferases; Dermatomyositis; El | 1964 |
CALCINOSIS UNIVERSALIS COMPLICATING DERMATOMYOSITIS. ITS TREATMENT WITH NA2 EDTA. REPORT OF TWO CASES IN CHILDREN.
Topics: Adolescent; Calcinosis; Calcium; Child; Dermatomyositis; Drug Therapy; Edetic Acid; Humans; Magnesiu | 1964 |
[VACUOLAR MYOPATHY IN DERMATOMYOSITIS (LUPUS ERYTHEMATOSUS)].
Topics: Anemia; Anemia, Aplastic; Anti-Bacterial Agents; Dermatomyositis; Dexamethasone; Humans; Lupus Eryth | 1964 |
DIAGNOSIS AND TREATMENT OF POLYMYOSITIS.
Topics: Adrenal Cortex Hormones; Classification; Clinical Enzyme Tests; Dermatomyositis; Diagnosis; Drug The | 1964 |
[RECURRENCE OF DERMATOMYOSITIS FOLLOWING SEVERAL YEARS OF APPARENT RECOVERY].
Topics: Child; Dermatomyositis; Dexamethasone; Drug Therapy; Humans; Neoplasms; Physiological Phenomena; Pre | 1965 |
[Subacute form of dermatomyositis. Effect of hormonal therapy].
Topics: Child; Dermatomyositis; Humans; Infant; Prednisone | 1959 |
[Can we predict the risk of malignancy associated with dermatomyositis?].
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 2003 |
A case of edematous dermatomyositis.
Topics: Aged; Biopsy; Dermatomyositis; Drug Therapy, Combination; Edema; Electromyography; Fatal Outcome; Fe | 2003 |
[Flagellate erythema in paraneoplastic dermatomyositis].
Topics: Carcinoma, Squamous Cell; Dermatomyositis; Diagnosis, Differential; Erythema; Glucocorticoids; Human | 2004 |
Calcinosis cutis complicating adult-onset dermatomyositis.
Topics: Adult; Calcinosis; Dermatomyositis; Diagnosis, Differential; Diltiazem; Drug Administration Schedule | 2004 |
Acute thrombotic thrombocytopenic purpura following doxycycline treatment of Chlamydia pneumoniae infection in a patient with dermatomyositis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents; Chlamydia; Chlamydia Infectio | 2004 |
Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.
Topics: Adult; Autoimmune Diseases; Dermatomyositis; Female; Glucocorticoids; Humans; Hypertriglyceridemia; | 2005 |
[Association of systemic lupus erythematosus and dermatopolymyositis].
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Cyclophosphamide; Dermatomyositis; Humans; Immunosuppressiv | 2005 |
Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Autoantibodies; Cohort Studies; Dermatomyositis; | 2005 |
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
Topics: Alendronate; Calcinosis; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administrati | 2005 |
[The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].
Topics: Anti-Inflammatory Agents; Dermatomyositis; Dose-Response Relationship, Drug; Humans; Myositis, Inclu | 2005 |
Skin rash and muscle weakness.
Topics: Dermatomyositis; Exanthema; Female; Glucocorticoids; Humans; Middle Aged; Muscle Weakness; Prednison | 2005 |
[Dermatomyositis in children. Report of 5 cases].
Topics: Adolescent; Child; Dermatomyositis; Electromyography; Enzymes; Female; Follow-Up Studies; Humans; In | 1977 |
Dermatomyositis complicated with Kaposi sarcoma: a case report.
Topics: Aged; Antineoplastic Agents, Phytogenic; Dermatomyositis; Female; Humans; Immunoglobulins, Intraveno | 2007 |
[Juvenile dermatomyositis in 12 years old girl].
Topics: Antibodies, Antinuclear; Child; Dermatomyositis; Erythema; Female; Glucocorticoids; Humans; Muscle W | 2005 |
Rituximab as therapy for refractory polymyositis and dermatomyositis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Azathioprine; B-Lymp | 2006 |
Mycophenolate mofetil in dermatomyositis: is it safe?
Topics: Adult; Aged; Bronchopneumonia; Dermatomyositis; Drug Administration Schedule; Drug Therapy, Combinat | 2006 |
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
Topics: Adult; Antibodies, Monoclonal; Dermatologic Agents; Dermatomyositis; Drug Resistance; Drug Therapy, | 2007 |
Idiopathic myelofibrosis associated with dermatomyositis.
Topics: Anti-Inflammatory Agents; Dermatomyositis; Female; Humans; Middle Aged; Prednisone; Primary Myelofib | 2006 |
Recurrent episodes of dermatomyositis-associated pneumonitis masquerading as hypersensitivity pneumonitis.
Topics: Adult; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Dermatomyositis; Diagnosis, Differentia | 2006 |
[Porokeratosis in a patient with dermatomyositis].
Topics: Aged; Dermatomyositis; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Methotrexat | 2006 |
Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy.
Topics: Abdominal Pain; Adolescent; Arteries; Chronic Disease; Combined Modality Therapy; Dermatomyositis; D | 2007 |
Amyopathic dermatomyositis--an uncommon presentation of dermatomyositis.
Topics: Adult; Arthralgia; Cyclosporine; Dermatologic Agents; Dermatomyositis; Exanthema; Glucocorticoids; H | 2007 |
[Polymyositis and dermatomyositis in esophageal cancer].
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Carcinoma, Squamous Cell; Dermatomyositis; Esophageal Neopla | 2007 |
Lipodystrophy and metabolic abnormalities in a case of adult dermatomyositis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositis; Drug Therapy, Combination; Female; Glucoco | 2007 |
Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis.
Topics: Antifungal Agents; Blotting, Western; Complement Membrane Attack Complex; Dermatomyositis; Endotheli | 2008 |
Leflunomide as adjuvant treatment of dermatomyositis.
Topics: Adjuvants, Immunologic; Adult; Aged; Dermatologic Agents; Dermatomyositis; Dose-Response Relationshi | 2008 |
Methotrexate-induced and Epstein-Barr virus-associated B-cell lymphoma of the spine: MR and PET/CT imaging.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Cyclophosphamide; Dermat | 2008 |
Bone mineral density in children exposed to chronic glucocorticoid therapy.
Topics: Adolescent; Arthritis, Juvenile; Bone Density; Calcium, Dietary; Child; Child, Preschool; Cross-Sect | 2008 |
Cardiac abnormalities in polymyositis/dermatomyositis.
Topics: Adult; Arrhythmias, Cardiac; Creatine Kinase; Dermatomyositis; Female; Heart; Heart Rate; Humans; Is | 1982 |
[Polydermatomyositis in the adult and its management].
Topics: Adrenal Cortex Hormones; Adult; Alcoholism; Dermatomyositis; Female; Humans; Male; Middle Aged; Neop | 1983 |
Corticosteroids in autoimmune disease.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Circadian Rhythm; Cyclophosphamide; Dermatomyositis; D | 1983 |
Course of treated juvenile dermatomyositis.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Chronic Disease; Dermat | 1984 |
[Steroid therapy and causes of death in dermatomyositis--report of 16 cases].
Topics: Adolescent; Adult; Dermatomyositis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone | 1984 |
Serial changes in nailfold capillary morphology in childhood dermatomyositis.
Topics: Capillaries; Child; Dermatomyositis; Humans; Male; Nails; Prednisone | 1983 |
Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.
Topics: Adolescent; Calcinosis; Child; Child, Preschool; Dermatomyositis; Female; Humans; Infant; Male; Musc | 1983 |
Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.
Topics: Adenocarcinoma; Adolescent; Adult; Azathioprine; Dermatomyositis; Drug Therapy, Combination; Female; | 1984 |
[Pediatric dermatomyositis. Apropos of 28 cases].
Topics: Adolescent; Child; Child, Preschool; Dermatomyositis; Female; Humans; Infant; Male; Prednisone; Prog | 1984 |
[Calcinosis of childhood dermatomyositis. Apropos of 10 cases].
Topics: Calcinosis; Child; Child, Preschool; Dermatomyositis; Female; Follow-Up Studies; Humans; Male; Predn | 1984 |
Inflammatory disorders of muscle. Cardiac abnormalities.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiomyopathies; Coronary Disease; Creatine Kinase; Dermatomyosi | 1984 |
Steroid therapy of dermatomyositis.
Topics: Adrenal Cortex Hormones; Calcinosis; Child; Dermatomyositis; Humans; Prednisone | 1984 |
[Cyclosporin A in dermatomyositis].
Topics: Cyclosporins; Dermatomyositis; Humans; Male; Middle Aged; Prednisone | 1984 |
Childhood dermatomyositis--a case report.
Topics: Adolescent; Dermatomyositis; Follow-Up Studies; Humans; Male; Prednisone | 1983 |
"Chronic" dermatomyositis: response to corticosteroids.
Topics: Child; Dermatomyositis; Female; Humans; Prednisone | 1980 |
Juvenile dermatomyositis: a clinical and immunologic study.
Topics: Adolescent; Antibodies, Antinuclear; Child; Child, Preschool; Complement System Proteins; Dermatomyo | 1980 |
Kaposi's sarcoma in a patient with dermatomyositis receiving immunosuppressive therapy.
Topics: Azathioprine; Cell Count; Dermatomyositis; Female; Humans; Immunosuppressive Agents; Methotrexate; M | 1982 |
[Immunoglobulins in dermatomyositis].
Topics: Adolescent; Adult; Aged; Dermatomyositis; Female; Humans; Immunoglobulins; Male; Middle Aged; Predni | 1982 |
[Infantile dermatomyositis: apropos of 2 cases].
Topics: Child; Dermatomyositis; Electromyography; Female; Humans; Muscles; Prednisone | 1982 |
Diffuse fasciitis with eosinophilia in childhood.
Topics: Adolescent; Dermatomyositis; Diagnosis, Differential; Eosinophilia; Fasciitis; Female; Humans; Immun | 1982 |
Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis.
Topics: Child; Child, Preschool; Cyclophosphamide; Dermatomyositis; Dose-Response Relationship, Drug; Drug T | 1980 |
Dermatomyositis: cutaneous clues to subclinical myositis.
Topics: Adult; Dermatomyositis; Diagnosis, Differential; Female; Humans; Prednisone; Raynaud Disease | 1981 |
[Electromyography in children with polymyositis (author's transl)].
Topics: Adolescent; Child; Dermatomyositis; Electromyography; Female; Humans; Male; Myositis; Prednisone; Ti | 1981 |
Polymyositis with pulmonary infiltrate and pleural effusion.
Topics: Aged; Dermatomyositis; Female; Humans; Lung Diseases; Myositis; Pleural Effusion; Prednisone | 1980 |
Muscular strength as an index of response to therapy in childhood dermatomyositis.
Topics: Adolescent; Azathioprine; Biomechanical Phenomena; Child; Child, Preschool; Creatine Kinase; Dermato | 1981 |
Plasmapheresis in childhood dermatomyositis.
Topics: Child, Preschool; Chlorambucil; Dermatomyositis; Female; Humans; Immunoglobulin G; Immunoglobulin M; | 1981 |
Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique.
Topics: Adult; Aged; Biopsy; Child; Dermatomyositis; Female; Follow-Up Studies; HTLV-I Infections; Humans; M | 1995 |
A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis.
Topics: Adult; Aged; Cohort Studies; Dermatomyositis; Disability Evaluation; Disabled Persons; Disease Progr | 1995 |
Relapsing eosinophilic perimyositis.
Topics: Anti-Inflammatory Agents; Dermatomyositis; Eosinophilia; Humans; Male; Middle Aged; Prednisone; Recu | 1995 |
Severe hypertrichosis as an uncommon feature of juvenile dermatomyositis.
Topics: Child; Child, Preschool; Dermatomyositis; Female; Humans; Hypertrichosis; Male; Mexico; Prednisone | 1995 |
Mineral metabolism in children with dermatomyositis.
Topics: Absorption; Adolescent; Alkaline Phosphatase; Bone and Bones; Bone Density; Calcium; Child; Child, P | 1994 |
Chronic pneumomediastinum and subcutaneous emphysema: association with dermatomyositis.
Topics: Adult; Age of Onset; Biopsy, Needle; Bronchoscopy; Chronic Disease; Dermatomyositis; Fatal Outcome; | 1995 |
[A clinical analysis of cutaneous type dermatomyositis].
Topics: Adult; Child; Child, Preschool; Dermatomyositis; Female; Follow-Up Studies; Humans; Ibuprofen; Male; | 1994 |
Phosphorus 31 magnetic resonance spectroscopy for quantitative evaluation of therapeutic regimens in dermatomyositis.
Topics: Adenosine Triphosphate; Adult; Azathioprine; Dermatomyositis; Evaluation Studies as Topic; Female; F | 1995 |
Kienbock's disease--avascular necrosis of the carpal lunate bone--in a 7-year-old girl with dermatomyositis.
Topics: Carpal Bones; Child; Dermatomyositis; Female; Humans; Methylprednisolone; Osteochondritis; Prednison | 1994 |
[Dermatomyositis and Wilson disease].
Topics: Adolescent; Consanguinity; Dermatomyositis; Drug Therapy, Combination; Dysarthria; Female; Hepatolen | 1994 |
Tuberculous infection of skeletal muscle in a case of dermatomyositis.
Topics: Aged; Antitubercular Agents; Dermatomyositis; Female; Humans; Muscles; Prednisone; Tuberculosis | 1994 |
Strength in polymyositis and dermatomyositis: best outcome in patients treated early.
Topics: Biomechanical Phenomena; Creatine Kinase; Dermatomyositis; Female; Humans; Male; Middle Aged; Muscle | 1994 |
[Value of the association of corticoids and high-dose polyvalent intravenous immunoglobulins in the aggressive treatment of dermatomyositis].
Topics: Adult; Dermatomyositis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; | 1994 |
Photodermatitis in a 6-year-old child.
Topics: Child; Dermatomyositis; Diagnosis, Differential; Humans; Male; Photosensitivity Disorders; Prednison | 1993 |
[Intravenously administered immunoglobulins as a first-choice method in juvenile dermatomyositis].
Topics: Dermatomyositis; Female; Humans; Immunoglobulins, Intravenous; Middle Aged; Prednisone | 1993 |
Proton magnetic resonance imaging and spectroscopic studies of the pathogenesis and treatment of juvenile dermatomyositis.
Topics: Adolescent; Biopsy; Body Water; Dermatomyositis; Humans; Leg; Lipid Metabolism; Magnetic Resonance I | 1993 |
Cyclosporine treatment for dermatomyositis/polymyositis.
Topics: Azathioprine; Cyclosporine; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Polymy | 1993 |
Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis.
Topics: Administration, Oral; Adult; Aged; Chlorambucil; Creatine Kinase; Dermatomyositis; Drug Resistance; | 1993 |
Subcutaneous changes in dermatomyositis.
Topics: Adult; Creatine Kinase; Dermatomyositis; Female; Humans; Muscles; Panniculitis; Prednisone; Skin | 1993 |
Study of 45 cases of nasopharyngeal carcinoma with dermatomyositis.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Case-Control Studies; Combined Modality Therapy; Dermatomyosi | 1996 |
Juvenile dermatomyositis in a child infected with human parvovirus B19.
Topics: Anti-Inflammatory Agents; Antibodies, Viral; Base Sequence; Child; Dermatomyositis; DNA Primers; DNA | 1995 |
Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin.
Topics: Dermatomyositis; Drug Resistance; Female; Humans; Immunoglobulins, Intravenous; Middle Aged; Prednis | 1996 |
Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Child; Creatine Kinase; Dermatomyositis; Drug Admini | 1996 |
Dermatomyositis in pregnancy.
Topics: Adult; Dermatomyositis; Electromyography; Female; Humans; Immunosuppressive Agents; Methotrexate; Pr | 1996 |
Annular erythema, dermatomyositis, and Sjögren's syndrome.
Topics: Adult; Anti-Inflammatory Agents; Dermatomyositis; Erythema; Follow-Up Studies; Humans; Hydrocortison | 1996 |
Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Antimalarial | 1997 |
Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies--an interesting association.
Topics: Autoantibodies; Cryptogenic Organizing Pneumonia; Dermatomyositis; Glucocorticoids; Histidine-tRNA L | 1997 |
A woman with a post-vacation rash.
Topics: Antirheumatic Agents; Creatine Kinase; Dermatomyositis; Diagnosis, Differential; Female; Glucocortic | 1997 |
A patient with cutaneous T-cell lymphoma and dermatomyositis.
Topics: Aged; Anti-Inflammatory Agents; Dermatomyositis; Humans; Male; Mycosis Fungoides; Prednisone; Skin N | 1997 |
Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents; Dermatomyositis; Fatal Outcome; Female; Humans; Immunosuppressive A | 1997 |
Concurrence of celiac disease and juvenile dermatomyositis: result of a specific immunogenetic susceptibility?
Topics: Anti-Inflammatory Agents; Celiac Disease; Child; Creatine Kinase; Dermatomyositis; Female; Follow-Up | 1997 |
A woman with difficulty swallowing.
Topics: Aged; Anti-Inflammatory Agents; Deglutition Disorders; Dermatomyositis; Diagnosis, Differential; Dos | 1997 |
Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Juvenile; Child | 1997 |
Treacher-Collins syndrome and co-existing dermatomyositis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Chil | 1998 |
Dermatomyositis: a dermatology-based case series.
Topics: Adult; Child; Dermatomyositis; Female; Humans; Male; Middle Aged; Neoplasms; Prednisone; Retrospecti | 1998 |
[Prognostic factors of dermatomyositis: analysis of 119 cases].
Topics: Adolescent; Adult; Aged; Child; Dermatomyositis; Female; Glucocorticoids; Humans; Lung Diseases, Int | 1997 |
Dermatomyositis associated with bronchiolitis obliterans organizing pneumonia (BOOP).
Topics: Adult; Cryptogenic Organizing Pneumonia; Cyclophosphamide; Dermatomyositis; Diagnosis, Differential; | 1999 |
Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia.
Topics: Azathioprine; Biopsy, Needle; Creatine Kinase; Cryptogenic Organizing Pneumonia; Dermatomyositis; Di | 2000 |
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Topics: Adolescent; Adult; Calcinosis; Child; Cohort Studies; Dermatomyositis; Diabetes Mellitus, Type 1; Ed | 2000 |
[Nasopharyngeal carcinoma and dermatomyositis (analysis of 12 cases)].
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Dermatomyos | 1998 |
Interstitial pneumonitis and air leakage in juvenile dermatomyositis.
Topics: Child, Preschool; Cyclosporine; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Lung Dis | 2001 |
Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatomyositis; Drug Therapy, Combination; Fem | 2002 |
Dermatomyositis sine myositis and antisynthetase syndrome.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Antirheumatic Agents; Arthri | 2002 |
[Dermatomyositis and polymyositis: clinical aspects and treatment].
Topics: Anti-Inflammatory Agents; Creatinine; Dermatomyositis; Drug Therapy, Combination; Face; Humans; Immu | 2001 |
Cutaneous involvement of dermatomyositis can respond to Dapsone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dapsone; Dermatomyositis; Diagnosis, Differen | 2002 |
Prednisone effect on microvascular permeability in patients with inflammatory rheumatic diseases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Capillary Permeability; Dermatomyositis; Giant Cell Arteritis; H | 1979 |
Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy.
Topics: Agammaglobulinemia; Amyloidosis; Bence Jones Protein; Dermatomyositis; gamma-Globulins; Humans; Immu | 1975 |
Medical grand rounds.
Topics: Adult; Child; Dermatomyositis; Humans; Male; Methotrexate; Middle Aged; Myositis; Prednisone; Progno | 1979 |
Myasthenia in patients with dermatomyositis: clinical, electrophysiological and ultrastructural studies.
Topics: Adolescent; Adult; Biopsy; Dermatomyositis; Electromyography; Evoked Potentials; Fatigue; Female; Gl | 1978 |
Dermatomyositis in the pediatric patient.
Topics: Adolescent; Child; Child, Preschool; Dermatomyositis; Electromyography; Female; Humans; Infant; Infa | 1977 |
Persistance of activity in dermatomyositis of childhood.
Topics: Adolescent; Child; Child, Preschool; Dermatomyositis; Female; Humans; Male; Muscles; Prednisone; Rad | 1977 |
Treatment of dermatomyositis.
Topics: Azathioprine; Child, Preschool; Dermatomyositis; Female; Humans; Male; Methotrexate; Prednisone | 1977 |
Polymyositis and dermatomyositis: clinical problems.
Topics: Collagen Diseases; Dermatomyositis; Diagnosis, Differential; Humans; Myasthenia Gravis; Myositis; Ne | 1978 |
Methotrexate and azathioprine treatment of childhood dermatomyositis.
Topics: Azathioprine; Child; Child, Preschool; Dermatomyositis; Dose-Response Relationship, Drug; Drug Thera | 1977 |
Free serum ribonucleoprotein in mixed connective tissue disease and other connective tissue diseases.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Dermatomyositis; Humans; Lupus Erythematosus, System | 1978 |
Malignancy after immunosuppressive therapy.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Dermatomyositis; Female; Humans; Immunosuppression Therap | 1977 |
[Prognosis and current treatment of dermatomyositis].
Topics: Adult; Body Weight; Calcinosis; Child; Dermatomyositis; Humans; Prednisone; Prognosis | 1977 |
Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone.
Topics: Child; Child, Preschool; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Male; Methotrex | 1979 |
[A case of dermatomyositis with a very unusual development and histology].
Topics: Aged; Dermatomyositis; Humans; Male; Muscles; Prednisone; Tuberculosis, Miliary | 1979 |
Treatment of dermatomyositis with methotrexate and prednisone.
Topics: Aged; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Methotrexate; Prednisone | 1979 |
Myoglobinemia in inflammatory myopathies.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Collagen Diseases; Complement Fixation Tests; | 1977 |
Polymyositis-dermatomyositis: a perplexing disorder.
Topics: Activities of Daily Living; Clinical Enzyme Tests; Dermatomyositis; Electromyography; Female; Humans | 1977 |
[Treatment of scleroderma and dermatomyositis in childhood].
Topics: Adolescent; Age Factors; Aluminum Hydroxide; Anabolic Agents; Child; Cyclophosphamide; Dermatomyosit | 1978 |
[Problems of disseminated lupus erythematosus in infants and children].
Topics: Arthritis, Rheumatoid; Azathioprine; Child; Child, Preschool; Chloroquine; Dermatomyositis; Female; | 1978 |
[Polymyositis: clinico-pathogenetic, histological and electromyographic aspects].
Topics: Adult; Age Factors; Child, Preschool; Dermatomyositis; Diagnosis, Differential; Electromyography; Fe | 1977 |
Dermatomyositis and Malignancy.
Topics: Breast Neoplasms; Dermatomyositis; Female; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Pr | 1977 |
Small blood vessel involvement in childhood dermatomyositis. An ultrastructural study of a case.
Topics: Capillaries; Child, Preschool; Dermatomyositis; Humans; Male; Microcirculation; Muscles; Prednisone; | 1977 |
[Presentation of a case of dermatomyositis].
Topics: Adrenal Cortex Hormones; Child, Preschool; Dermatomyositis; Diagnosis, Differential; Female; Humans; | 1977 |
[2 patients with polymyositis; an attempt at an outline].
Topics: Adolescent; Autoimmune Diseases; Dermatomyositis; Female; Humans; Male; Middle Aged; Myositis; Predn | 1977 |
Letter: Treatment of dermatomyositis.
Topics: Azathioprine; Dermatomyositis; Humans; Prednisone | 1976 |
Treatment of dermatomyositis in childhood.
Topics: Azathioprine; Blood Sedimentation; Calcinosis; Child; Child, Preschool; Creatine Kinase; Dermatomyco | 1976 |
Hereditary complement (C2) deficiency with dermatomyositis.
Topics: Biopsy; Blood Bactericidal Activity; Chemotaxis; Complement Fixation Tests; Complement System Protei | 1975 |
Fatal pulmonary involvement in dermatomyositis.
Topics: Anti-Bacterial Agents; Bronchopneumonia; Child; Dermatomyositis; Diagnostic Errors; Duodenal Ulcer; | 1975 |
Clinical Grand Rounds. A case of dermatomyositis.
Topics: Adult; Biopsy; Creatine Kinase; Dermatomyositis; Electromyography; Female; Humans; Immunoglobulin M; | 1975 |
Muscles weakness? It may be polymyositis.
Topics: Cyclophosphamide; Dermatomyositis; Diagnosis, Differential; Humans; Muscular Diseases; Myositis; Pre | 1976 |
Methotrexate treatment of recalcitrant childhood dermatomyositis.
Topics: Adolescent; Calcium; Child; Child, Preschool; Dermatomyositis; Drug Evaluation; Drug Therapy, Combin | 1992 |
Pericardial tamponade in juvenile dermatomyositis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cardiac Tamponade; Child; Chloroquine; Dermat | 1992 |
Muscle regeneration and cell-mediated cytotoxicity in the autologous muscle culture of dermatomyositis.
Topics: Aged; Biopsy; Cells, Cultured; Cytotoxicity, Immunologic; Dermatomyositis; Humans; Male; Muscles; Pr | 1990 |
[Dermatopolymyositis, Gougerot-Sjögren's syndrome, Hashimoto's thyroiditis and glomerulopathy].
Topics: Dermatomyositis; Female; Glomerulonephritis; Humans; Middle Aged; Prednisone; Sjogren's Syndrome; Th | 1990 |
Dermatomyositis associated with multifocal lipoatrophy.
Topics: Buttocks; Child; Dermatomyositis; Humans; Lipodystrophy; Male; Panniculitis; Prednisone | 1990 |
Adjunctive use of hydroxychloroquine in childhood dermatomyositis.
Topics: Adolescent; Antineoplastic Agents; Child; Dermatomyositis; Drug Therapy, Combination; Female; Humans | 1989 |
Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis.
Topics: Adult; Aged; Cyclophosphamide; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Male; Myo | 1989 |
Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases.
Topics: Connective Tissue Diseases; Dermatomyositis; Dyspnea; Female; Humans; Middle Aged; Muscular Diseases | 1989 |
[Dermatomyositis in children].
Topics: Child; Dermatomyositis; Humans; Prednisone | 1989 |
[Conference at the Salpêtrière Hospital. June 1987. Progressive spastic paraparesis and dermatomyositis. Epidural lipomatosis during corticosteroid therapy of dermatomyositis].
Topics: Dermatomyositis; Epidural Space; Female; Humans; Lipomatosis; Middle Aged; Paraplegia; Prednisone; S | 1989 |
Retinopathy of dermatomyositis.
Topics: Child, Preschool; Dermatomyositis; Electromyography; Fundus Oculi; Humans; Male; Methylprednisolone; | 1985 |
Inclusion body myositis: a case with associated collagen vascular disease responding to treatment.
Topics: Azathioprine; Cell Nucleus; Dermatomyositis; Drug Therapy, Combination; Humans; Inclusion Bodies; Ma | 1985 |
Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis.
Topics: Adolescent; Adult; Aged; Creatine Kinase; Dermatomyositis; Drug Administration Schedule; Female; Hum | 1988 |
Coexistence of Paget's disease and dermatomyositis.
Topics: Dermatomyositis; Humans; Male; Middle Aged; Osteitis Deformans; Prednisone | 1988 |
[Removal of prednisone and prednisolone during plasma exchange].
Topics: Chromatography, High Pressure Liquid; Dermatomyositis; Humans; Muscular Diseases; Plasma Exchange; P | 1988 |
Antiinsulin antibodies and clinical characteristics of patients with systemic lupus erythematosus and other connective tissue diseases with steroid induced diabetes.
Topics: Adult; Aged; Dermatomyositis; Diabetes Mellitus, Type 1; Female; Giant Cell Arteritis; Humans; Insul | 1987 |
[Dermatomyositis in children: clinical course of 9 cases].
Topics: Child; Child, Preschool; Cyclophosphamide; Dermatomyositis; Female; Humans; Immunosuppressive Agents | 1987 |
['Difficult' children with muscular weakness; the importance of early diagnosis of dermatomyositis].
Topics: Child; Child, Preschool; Dermatomyositis; Female; Humans; Muscle Hypotonia; Prednisone; Prognosis; T | 1987 |
[Clinical study of dermato/polymyositis with onset in childhood].
Topics: Adolescent; Age Factors; Child; Dermatomyositis; Follow-Up Studies; Humans; Muscular Diseases; Predn | 1987 |
Childhood dermatomyositis. Clinical course and long-term follow-up.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Dermatomyositis; Drug Therapy, Combination; Femal | 1987 |
Influence of age at onset on the duration of treatment in idiopathic adult polymyositis and dermatomyositis.
Topics: Actuarial Analysis; Adult; Aged; Aging; Clinical Enzyme Tests; Creatine Kinase; Dermatomyositis; Fem | 1987 |
Juvenile dermatomyositis: histological findings and pathogenetic hypothesis for the associated skin changes.
Topics: Basement Membrane; Child; Cyclophosphamide; Dermatomyositis; Endothelium; Female; Humans; Male; Micr | 1986 |
Late recurrence of childhood dermatomyositis.
Topics: Child; Dermatomyositis; Female; Humans; Prednisone; Recurrence; Time Factors | 1986 |
Clinical and serologic features of patients with polymyositis or dermatomyositis.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Child; Child, Preschool; Dermatomyositis; Female; | 1985 |
Polymyositis/dermatomyositis: clinical features and outcome in 22 patients.
Topics: Actuarial Analysis; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Antinuclear; Dermatomyositis; | 1985 |
[Dermatomyositis and monoclonal gammopathy].
Topics: Adult; Dermatomyositis; Humans; Hypergammaglobulinemia; Immunoglobulin G; Immunoglobulin kappa-Chain | 1985 |
[Plasma separation in severe juvenile dermatomyositis].
Topics: Azathioprine; Child; Combined Modality Therapy; Dermatomyositis; Drug Therapy, Combination; Humans; | 1985 |
[Dermatopolymyositis and pulmonary fibrosis associated with Gougerot-Sjogren syndrome. Study of 3 cases].
Topics: Cyclophosphamide; Dermatomyositis; Female; Humans; Middle Aged; Prednisone; Pulmonary Alveoli; Pulmo | 1985 |
Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis.
Topics: Adult; Chlorambucil; Dermatomyositis; Drug Resistance; Female; Humans; Immunosuppressive Agents; Met | 1985 |
Treatment of corticosteroid-resistant polymyositis with methotrexate.
Topics: Administration, Oral; Adrenal Cortex Hormones; Chronic Disease; Dermatomyositis; Humans; Injections, | 1971 |
Measurements of disease activity in dermatomyositis.
Topics: Adult; Aspartate Aminotransferases; Biomechanical Phenomena; Biopsy; Creatine Kinase; Dermatomyositi | 1971 |
[Heart diseases in collagenoses].
Topics: Adult; Amyloidosis; Cardiac Complexes, Premature; Cardiomegaly; Collagen Diseases; Coronary Disease; | 1970 |
Pityriasis rubra pilaris with muscle and joint involvement.
Topics: Arthritis; Aspirin; Blood Sedimentation; Chloroquine; Creatine; Dermatomyositis; Humans; Latex Fixat | 1973 |
[The treatment of dermatomyositis].
Topics: Adolescent; Adrenocorticotropic Hormone; Alpha-Globulins; Antibodies, Antinuclear; Antimetabolites; | 1974 |
Treatment of dermatomyositis with methotrexate.
Topics: Adrenal Cortex Hormones; Adult; Aged; Breast Neoplasms; Carcinoma; Dermatomyositis; Female; Humans; | 1968 |
[Detection of antibodies to soluble nucleoprotein and to deoxyribonucleic acid using a radioimmunologic method].
Topics: Antibodies; Antibodies, Antinuclear; Arthritis, Rheumatoid; Azathioprine; Collagen Diseases; Dermato | 1974 |
[Calcinosis universalis in dermatomyositis].
Topics: Azathioprine; Calcinosis; Cardiomegaly; Child; Dermatomyositis; Diagnosis, Differential; Electromyog | 1969 |
[Wagner-Hepp-Unverricht disease (dermatomyositis). Analytical study of personal observations].
Topics: Adrenocorticotropic Hormone; Adult; Dermatomyositis; Female; Humans; Prednisone | 1967 |
[ACTH-prednisone-penicillin in the treatment of dermatomyositis with generalized interstitial calcinosis].
Topics: Adrenocorticotropic Hormone; Calcinosis; Child; Dermatomyositis; Female; Humans; Penicillins; Predni | 1966 |
[Therapeutic effect of alpha-tocopher- yl-quinone on muscular disorders of hyperthyroidism and of prolonged treatment by corticoids and antimitotics].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Asthenia; Busulfan; Chlorambucil; Cobal | 1969 |
Juvenile dermatomyositis.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Age Factors; Anabolic Agents; Child; Child, Preschoo | 1970 |
[Hydroxyproline excretion in urine in chronic connective tissue disease].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Collagen | 1970 |
[Case of dermatomyosits treated with cyclophosphamide and corticosteroids].
Topics: Cyclophosphamide; Dermatomyositis; Female; Humans; Middle Aged; Prednisone; Remission, Spontaneous | 1974 |
Polymyositis and dermatomyositis.
Topics: Biopsy; Dermatomyositis; Female; Humans; Male; Methotrexate; Muscles; Muscular Diseases; Neoplasms; | 1973 |
Dermatomyositis with cerebral vasculitis in a patient with agammaglobulinemia.
Topics: Adolescent; Agammaglobulinemia; Arthritis, Rheumatoid; Autopsy; Cerebral Angiography; Cerebrovascula | 1972 |
[Peptic ulcers appearing and cured under uninterrupted corticoid therapy].
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Dermatomyositis; Endoscopy; Female; Hep | 1974 |
Pulmonary fibrosis masking polymyositis. Remission with corticosteroid therapy.
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Humans; Male; Muscular Diseases; Prednisone; Pulmona | 1972 |
Dermatomyositis complicating pregnancy.
Topics: Adult; Dermatomyositis; Diagnosis, Differential; Female; Humans; Infant, Newborn; Isoniazid; Lupus E | 1973 |
[Dermatomyositis syndromes and their immunosuppressive therapy. (Report of 4 cases)].
Topics: Adult; Azathioprine; Dermatomyositis; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Pr | 1973 |
Ophthalmoplegia in dermatomyositis.
Topics: Aspartate Aminotransferases; Creatine Kinase; Dermatomyositis; Diagnosis, Differential; Edrophonium; | 1973 |
Letter: Multiple actinic keratoses of the forehead.
Topics: Administration, Topical; Dermatomyositis; Fluorouracil; Humans; Inflammation; Keratosis; Male; Middl | 1973 |
Cricopharyngeal achalasia in dermatomyositis.
Topics: Biopsy; Deglutition Disorders; Dermatomyositis; Dilatation; Electromyography; Esophagoscopy; Humans; | 1973 |
Letter: Dermatomyositis: urinary chromatographic findings by alkaline autoanalysis for peptides (one case).
Topics: Adolescent; Autoanalysis; Chromatography, Ion Exchange; Dermatomyositis; Female; Humans; Male; Metho | 1973 |
Methotrexate therapy in polymyositis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Aspartate Aminotra | 1973 |
Interstitial pneumonitis in association with polymyositis and dermatomyositis.
Topics: Adult; Aged; Biopsy; Dermatomyositis; Female; Humans; Lung; Male; Middle Aged; Myositis; Prednisone; | 1974 |
Childhood polymyositis. A follow-up study with special reference to treatment with corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Biopsy; Child; Child, Preschool; Clinical Enzyme Tests; Dermato | 1974 |
Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Creatine Kinase; Dermatomyositis; Drug Therapy, Combination; Female; Humans | 1974 |
Prognosis in childhood dermatomyositis.
Topics: Adolescent; Aspartate Aminotransferases; Biopsy; Blood Protein Electrophoresis; Child; Child, Presch | 1972 |
Polymyositis and interstitial lung disease.
Topics: Adult; Dermatomyositis; Female; Humans; Isoniazid; Middle Aged; Prednisone; Pulmonary Alveoli; Pulmo | 1972 |
Dermatomyositis.
Topics: Adult; Azathioprine; Dermatomyositis; Humans; Male; Methotrexate; Prednisone; Remission, Spontaneous | 1972 |
[Experiences in administration of antimetabolites in treatment of dermatomyosis].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antimetabolites; Azathioprine; Dermatomyositis; Female; Follow | 1972 |
Myoglobinuric acute renal failure in a case of dermatomyositis.
Topics: Acute Kidney Injury; Adult; Autopsy; Dermatomyositis; Female; Humans; Muscles; Myoglobinuria; Predni | 1972 |
Polymyositis with facioscapulohumeral distribution.
Topics: Child; Creatine Kinase; Dermatomyositis; Electromyography; Enzymes; Facial Muscles; Female; Humans; | 1971 |
[Diagnostic problems in proximal myasthenia].
Topics: Adult; Dermatomyositis; Diagnosis, Differential; Electromyography; Female; Humans; Male; Middle Aged | 1971 |
Myoglobinuria.
Topics: Biopsy; Dermatomyositis; Diagnosis, Differential; Female; Hemoglobinuria; Humans; Middle Aged; Muscl | 1971 |
Dermatomyositis. Importance of early diagnosis.
Topics: Adult; Dermatomyositis; Diagnosis, Differential; Female; Humans; Neoplasms; Prednisone; Trichinellos | 1971 |
[Immunosuppressive treatment of collagen diseases].
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi | 1969 |
Steroid-induced lipemia. A complication of high-dosage corticosteroid therapy.
Topics: Adolescent; Dermatomyositis; Dietary Fats; Female; Glucose Tolerance Test; Humans; Hyperlipidemias; | 1970 |
Dermatomyositis with ulceration.
Topics: Adult; Dermatomyositis; Female; Humans; Prednisone; Skin Ulcer | 1970 |
Cystinuria and dermatomyositis.
Topics: Adolescent; Amino Acids; Chromatography, Paper; Cystinuria; Dermatomyositis; Electromyography; Femal | 1970 |
[Clinical picture and therapy of dermatomyositis].
Topics: Adolescent; Calcinosis; Child; Dermatomyositis; Erythema; Female; Humans; Indomethacin; Prednisone | 1970 |
Striae.
Topics: Acetates; Adult; Aluminum; Axilla; Candidiasis; Child; Dermatomyositis; Eyelid Diseases; Female; Hum | 1971 |
[Polymyositis and related disorders].
Topics: Adult; Autoimmune Diseases; Child; Child, Preschool; Dermatomyositis; Diagnosis, Differential; Elect | 1971 |
Lung involvement in polymyositis.
Topics: Biopsy; Dermatomyositis; Diagnosis, Differential; Humans; Male; Middle Aged; Prednisone; Pulmonary F | 1971 |
[Apropos of a case of malignant eosinophilic collagenosis].
Topics: Adult; Cardiomyopathies; Collagen Diseases; Dermatomyositis; Eosinophilia; Humans; Male; Mitral Valv | 1967 |
[On the differential diagnosis of progressive scleroderma].
Topics: Child; Dermatomyositis; Diagnosis, Differential; Humans; Male; Physical Therapy Modalities; Predniso | 1967 |
Pulmonary involvement in polymyositis: report of a case with response to corticosteroid therapy.
Topics: Adult; Biopsy; Dermatomyositis; Diagnosis, Differential; Female; Humans; Lung Diseases; Microscopy, | 1968 |
[Acute dermatomyositis with major stigma of acute lupus erythematosus].
Topics: Acute Disease; Dermatomyositis; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, System | 1968 |
Dermatomyositis.
Topics: Dermatomyositis; Edema; Female; Humans; Mercaptopurine; Middle Aged; Orbit; Prednisone | 1969 |
Dermatomyositis in a child.
Topics: Azathioprine; Child; Dermatomyositis; Female; Humans; Prednisone | 1969 |